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ABSTRACT 
Background: Salivary diagnostics is an emerging field that has progressed through 
several important developments in the past decade.  Identification and standardization of 
salivary biomarkers can be used to develop compact point-of-care devices for rapid 
analysis and this can be used as an accurate screening tool for the diagnoses of systemic 
diseases in the near future. 
Objective: To evaluate the presence of high sensitive C-reactive protein (hs-CRP), 
Myoglobin(MYO) in the unstimulated whole saliva (UWS) of acute myocardial infarct 
patients and controls and thereby investigate the utility of saliva as an alternative 
diagnostic fluid for Acute Myocardial Infarction (AMI). 
Materials and Methods: UWS was collected from AMI patients at three different time 
periods; 6-12 hours, 24-48 hrs and 48-72 hrs of onset of signs and symptoms of AMI and 
the salivary hs-CRP and myoglobin expression was compared with normal controls. Hs-
CRP was evaluated using Immunoturbidimetric assay (IT) and myoglobin using Enzyme 
linked immunosorbant assay (ELISA). 
Results: Expression of salivary hs-CRP levels (mg/L) were higher in AMI group than 
normal controls. Salivary myoglobin levels showed increase in expression in periodontitis 
controls and normal controls when compared to the AMI group samples collected at 24-48 
hrs and 48-72 hrs (P=0.013 and P= 0.022 respectively). In AMI patients myoglobin levels 
showed a significant increase in samples collected at 6-12 hrs (P=0.018) than in the 
samples collected at 24-48 hrs and 48-72 hrs (P=0.009 and P=0.015 respectively). The 
salivary myoglobin expression showed a significant increase in the samples collected at 6-
12hrs from NSTEMI patients (P=0.043) than in the samples collected from STEMI 
patients in AMI group.  
Conclusion: Hs-CRP using Immunoturbidimetry showed consistent results, while 
myoglobin results by ELISA were inconsistent, this inconsistency we feel was due to its 
sensitivity to long term storage. It is thus preferable to analyze the samples immediately or 
prevent repeated freeze-thaw cycle. Salivary analysis of cardiac biomarkers needs more 
sensitive techniques of high sensitivity and specificity to be utilised as a diagnostic tool 
and further studies are to be done to arrive at a reference range for salivary hs-CRP and 
myoglobin levels.  
Keywords: Unstimulated whole saliva, salivary biomarkers, hs-CRP, Myoglobin, Acute 
Myocardial Infarction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     
Introduction 
     
 
Saliva as a diagnostic tool has the potential to revolutionize screening 
technology for systemic as well as malignant diseases. Identification and 
standardization of salivary biomarkers are being done to develop compact point-of-
care devices for rapid analysis that can be used as an accurate screening tool for the 
diagnosis of systemic diseases
1
. 
Human saliva is a biological fluid with enormous diagnostic potential. Because 
saliva can be non-invasively collected, it provides an attractive alternative for blood, 
serum or plasma. It has been postulated that the blood concentrations of many 
components are reflected in saliva. Saliva harbours a wide array of proteins, which can 
be informative for the detection of diseases. Profiling the proteins in saliva over the 
course of disease progression could reveal potential biomarkers indicative of different 
stages of diseases, which may be useful in medical diagnostics
2
. Like blood, saliva 
contains many protein and RNA molecules, both of which are encoded by genes
3
. 
 Whole saliva or Oral fluid is composed primarily of saliva secreted by the 
three major paired salivary glands the parotid, submandibular and sublingual and 
numerous minor salivary glands located throughout the oral cavity, it also contains 
gingival crevicular fluid, sloughed oral epithelial cells, nasopharyngeal discharge, food 
debris, and bacteria and their products, despite this, whole saliva reflects the secretions 
of major salivary glands and hence a valuable tool in research and diagnostic 
purposes
4, 5, 6 
. 
Early diagnosis of myocardial infarction (MI) is a clinical challenge and there 
are numerous evolving algorithms. Salivary biomarkers including C-reactive protein, 
myoglobin and myeloperoxidase were identified as potential diagnostic markers along 
with electrocardiogram findings and serum biomarkers in acute myocardial infarct 
(AMI) patients
7
. 
Currently, AMI is identified by detection of rise and/or fall of cardiac 
biomarkers (preferably cardiac troponin-I/cTnI) together with evidence of myocardial 
ischemia based on ECG or imaging
8
. Despite tremendous progress in developing new 
diagnostic and screening methods, a substantial number of AMI cases today are missed 
or diagnosed too late to offer effective therapies. There is a subset of patients in whom 
there is no ECG changes (Non-ST elevated MI) at the initial stage, in these patient’s 
serum biomarkers are the only tool to diagnose myocardial necrosis. However these 
measurements require time and delays therapy and affect prognosis
7
.
 
C-reactive protein (CRP) is an acute phase reactant that is produced by the liver 
in response to stimuli from inflammatory cytokines. It is non-specific but a sensitive 
marker of systemic inflammation. Conventionally CRP is measured as a systemic 
marker in tissue injury and infection, and therefore conventional CRP assays are 
calibrated to measure dynamic increase in CRP concentration and not able to detect 
low levels of increase due to subtle inflammation as in atherosclerosis
9
.  
The newer high sensitive CRP (hs-CRP) assays measures low level increase of 
CRP
9, 10
. Measurement of elevated CRP by high sensitivity assays serves as a predictor 
or risk factor for atherosclerosis progression in apparently healthy individuals and also 
serves as a prognostic factor in patients with already diagnosed atherosclerotic 
disease
11
.   
Myoglobin (MYO), the oxygen binding heme protein constitutes about 2% in 
both skeletal and cardiac muscle. Myoglobin is the first marker to rise after AMI. The 
advantages of myoglobin in early diagnosis of myocardial infarction are its high early 
sensitivity and the possibility of rapidly assessing the success of thrombolytic 
therapy
12
. 
In this study our objective was to identify and assess salivary biomarkers which 
are seen in serum of patients with myocardial infarction. In this study we are going to 
evaluate the levels of hs-CRP and MYO in the saliva of AMI patients. These 
biomarkers are increased in the serum of AMI patients
7, 12, 13
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Aims and Objectives 
     
 
AIM 
To evaluate the presence of high sensitive C-reactive protein (hs-CRP) and 
Myoglobin (MYO) in the unstimulated whole saliva (UWS) of acute myocardial 
infarct (AMI) patients and controls. 
 
OBJECTIVES 
 To evaluate the presence of high sensitive C-reactive protein (hs-CRP) in the 
UWS of AMI patients using Immunoturbidimetric assay (IT). 
 To evaluate the presence of myoglobin (MYO) in the UWS of AMI patients using 
Solid phase Sandwich- Enzyme linked immunosorbant assay (ELISA).  
 To evaluate the presence of hs-CRP, and MYO in the UWS of controls. 
 
NULL HYPOTHESIS 
Levels of hs-CRP and MYO are same in the saliva and serum of AMI patients. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Materials and Methods  
     
 
INSTITUTIONAL REVIEW BOARD APPROVAL 
Institutional Review Board (IRB) approval was obtained for this project 
(Annexure I A & I B). The study protocol was submitted to the IRB (Annexure II).  
All samples were collected after obtaining informed consent from the subjects. 
(Annexure III) 
 
PATIENT SELECTION AND SAMPLE COLLECTION 
To evaluate 30 study subjects (AMI patients) and 30 controls (healthy subjects) 
which include 15 with periodontitis and 15 without periodontitis of both gender in the 
adult population.  
The Study subjects were AMI patients who were admitted with the signs and 
symptoms of AMI to the cardiac care unit (CCU) of Madras Medical Mission hospital 
(MMM), Madurai Meenakshi Mission Hospital and Research Centre (MMHRC) and 
Voluntary health services and hospital (VHS).  
Study controls were patients attending the outpatient department of Ragas 
Dental College and Hospitals. 
 
STUDY GROUPS (Annexure IV) 
Group I: Unstimulated saliva from 30 acute myocardial infarct patients   
Group II: Normal subjects (controls)    
 IIA - Unstimulated saliva from 15 controls with periodontitis 
 IIB - Unstimulated saliva from 15 apparently healthy controls without 
periodontitis  
 
Inclusion criteria for Group I 
Subjects with signs and symptoms of MI
8
. 
o Ischemic chest pain 
o Subjects showing ST elevation in ECG 
o Subjects without ST elevation but with clinical symptoms of MI. 
Exclusion criteria for Group I 
Subjects who had fever, stroke and autoimmune diseases were excluded 
        Inclusion criteria for Group II A 
Subjects with periodontitis 
Criteria used for assessing Periodontitis
14
:  
1. Plaque scores more than 30% of sites 
2. Bleeding scores more than 30% of sites 
3. Probing depth greater than or equal to 3mm 
4. Clinical attachment loss greater than or equal to 2mm 
       Inclusion criteria for Group II B  
Healthy, age and gender matched subjects. 
Exclusion criteria for Group II B 
o Subjects without cardio vascular disease and other metabolic and systemic 
diseases such as Diabetes mellitus. 
o Subjects who were not on antibiotics or any other medications during the past 2 
weeks 
 
 
 
METHOD FOR COLLECTING SALIVA (Group I) 
 Unstimulated saliva from AMI patients was collected thrice, first sample was 
collected within 6-12 hours of onset of signs and symptoms of AMI, second 
sample after 24 hours and before 48 hours and third sample after 48 hours and 
before 72 hours of onset of sign and symptoms. 
 Unstimulated whole saliva was collected in a sterile container. 
Saliva collection in group I 
1. Patients were conscious and were able to breathe without the help of oxygen 
mask. 
2. Patients were seated in a semi reclined comfortable position  
3. The patients were given drinking water (bottled) and asked to rinse their mouth 
out well (without drinking the water). 
4. Five minutes after this oral rinse, the patients were asked to spit whole saliva 
(WS) into a sterile container. 
5. The subjects were instructed to refrain from talking. The subject was asked to 
drop down the head and  let the saliva run naturally to the front of the mouth, hold 
for a while and spit into the sterilized container provided for about once a minute 
for up to 10 minutes. The goal for each whole saliva donation was approximately 
5ml. The subjects were asked not to cough up mucus or vomit. (Samples diluted 
with mucus or vomit was discarded). 
6. Collected samples were labelled with a sample id number and kept at 4 degree 
Celsius during transport. 
7. Detailed case history and all medications taken and prescribed were documented. 
8. Time and date of sample collection was recorded 
Things to avoid: (Prior to collection of second and third samples) 
1. Brushing teeth within 1 hour prior to collection. 
2. Using salivary stimulants: chewing gum, lemon drops, granulated sugar. 
3. Consuming a major meal within 1 hour prior to collection. 
4. Consuming acidic or high sugar foods within 20 minutes prior to collection. 
Method for collecting Saliva (Group II A and II B) 
Salivary collection was done according to the technique by Navazesh et al 
15
.   
Unstimulated whole saliva was collected from controls between 9 to 12 am. The 
subjects were advised to rinse his or her mouth several times with drinking water. The 
subjects were instructed to refrain from talking. The subjects were asked to drop down 
the head and  let the saliva run naturally to the front of the mouth, hold for a while and 
spit into the sterilized container provided, about once a minute for up to 10 minutes. 
The goal for each whole saliva donation was approximately 5ml. 
Things to avoid:  
1. Brushing teeth within 1 hour prior to collection. 
2. Using salivary stimulants: chewing gum, lemon drops, granulated sugar. 
3. Consuming a major meal within 1 hour prior to collection. 
4. Consuming acidic or high sugar foods within 20 minutes prior to collection. 
5. Consumption of alcohol 12 hours prior to collection of saliva. 
 
STORAGE 
 Collected samples were centrifuged at 3500rpm for 15 to 20 minutes at -20 
degrees Celsius. 
 The supernatant was aliquoted in 4 separate micro centrifuge tubes and 
sediments were stored separately. Samples were stored at -70 degrees Celsius 
till analysis in the deep freezer of Department of Oral and Maxillofacial 
Pathology, Ragas Dental College and Hospitals. 
 
ARMAMENTARIUM 
     1.  Oral examination devices (Gloves, Mask, Mouth mirror, Williams probe) 
2. Centrifuge Tubes   (1.5ml) 
3. Micropipettes 
4. Micropipette tips ( 20µl, 100µl, 200 µl,1000 µl)  
5. Cooling Centrifuge 
6.  -70 degrees Celsius ultra low temperature storage cabinet 
      7. Sterile containers for saliva collection 
      8.   Ice pack (for transfer)    
    9.  MYOGLOBIN ELISA kit (Biocheck inc
TM
.USA) 
 Automatic washer 
 ELISA reader 
   10. HsCRP Immunoturbidimetric kit ( BioSystems S.A
TM
, Spain) 
 CS400 automatic analyser 
 
 
 
 
 
Myoglobin levels were assessed by ELISA and the absorbance measured at 450 
nanometres (nm) and  hs-CRP levels were assessed by IT assay and the absorbance 
measured at 450 nm. 
 
PROCEDURE   
Enzyme linked Immunosorbant Assay (ELISA-Biocheck.inc
TM
.USA) for 
quantitative determination of Myoglobin. 
Contents and Reagents 
Antibody-Coated Wells (1 plate, 96 wells) 
Microtiter wells coated with murine monoclonal anti-myoglobin. 
Reference Standard Set (1.0 ml/vial, 1 set/kit) 
Prediluted (10 fold) standards contains 0, 25, 100, 250, 500, and 1000 ng/ml 
myoglobin, liquid, ready-to-use.  
Enzyme Conjugate Reagent (22 ml/vial) 
Contains goat anti-myoglobin antibody conjugated to horseradish peroxidise in Tris 
Buffer-BSA solution with preservatives. 
Substrate-TMB Reagent (11 ml/bottle) 
Contains one-step TMB solution. 
Stop Solution (1 bottle, 11 ml/bottle) 
Contains diluted hydrochloric acid (1N HCl). 
 
 
 
 
ASSAY PROCEDURE - ELISA 
All reagents were brought to room temperature (18-25°C) before use. 
 
To the 96 antibody coated microtitre wells, 20μl of prediluted myoglobin standards 
(std≠1 to std≠5), controls and undiluted whole saliva samples were added to the 
appropriate wells.  
 
200 μl of Enzyme Conjugate Reagent was added into each well, and incubated at room 
temperature for 45 minutes. 
 
The incubated microwells were rinsed 5times with distilled water by automatic washer 
and the residual water drops removed by striking the wells onto absorbent paper. 
 
100 μl of TMB Reagent solution was added into each well and incubated at room 
temperature for 20 minutes 
 
As the standards and samples develop blue colour, the reaction was stopped by adding 
100 μl of stop solution into each well.  
 
After all the blue colour changes into yellow colour completely, the microtitre wells 
were read at an absorbance of 450 nm by a microtitre well reader. 
 
 
 
 Quality control-ELISA 
 The absorbance (Y axis) of the colour complex is then measured and the 
generated values for each pre diluted standard were plotted against the expected 
concentration (X axis) forming a standard curve. This standard curve was then 
used to accurately determine the concentration of myoglobin in the samples 
tested. (Annexure V) 
 
IMMUNOTURBIDIMETRIC ASSAY (IT) TO DETERMINE hs-CRP 
(BioSystems S.A
TM
. Spain) 
Contents and composition 
1. Reagent A(1x40 ml):  Glycine buffer 0.1 mol/L, sodium azide 0.95 g/L 
2. Reagent B (1x10 ml): Suspension of latex particles coated with anti-human 
CRP antibodies, sodium azide 0.95g/L. 
3. Hs-CRP Standard 
Assay procedure 
 The working reagent was prepared by pouring Reagent B vial into Reagent 
A bottle. 
 The working reagent, the standard and the sample were brought to room 
temperature (37°c). 
 1.5 ml of working reagent and 20 μl of the standard and sample is pipetted 
into the cuvette and the cuvette is inserted into the instrument (CS400 auto 
analyser) 
 The absorbance is measured at 450nm after 10 minutes. 
 Quality control-IT 
The absorbance of each point of the standard curve was calculated (Y axis) and 
the values were plotted against the hs-CRP concentration (X axis). The hs-CRP 
concentrations in the samples were calculated by interpolation of its absorbance in the 
calibration curve. (Annexure V) 
 
STATISTICAL ANALYSIS 
The sample size of 30 in each group has been determined from the Standard 
Statistical Table (Expecting an effect value of 0.30% to detect the minimum difference 
between control and study groups under an approximate power of 80% with the level 
of significance of 0.05). 
Data entry, database management and all statistical calculations performed 
with the aid of the Statistical Package for the Social Sciences 
TM
 (SPSS, version 17) 
software. Descriptive statistics were calculated for all variables.  
Differences in means between more than two groups were assessed using the 
analysis of variance (ANOVA), followed by Tukey’s Honestly significant difference 
(Tukey HSD) test.  
To compare the expression of salivary myoglobin and hs-CRP between group I 
and group II t-test was done. A P value of < 0.05 was considered to be statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      
Review of Literature 
                                                
 
Saliva is an aqueous glandular fluid with a low protein content
16
 secreted into 
the mouth by three pairs of major salivary glands: Parotid, submandibular and 
sublingual glands and numerous minor salivary glands present in the labial mucosa, 
buccal mucosa, soft palate and tongue. The salivary secretion is either mucous i.e. rich 
in mucoproteins or serous i.e. watery or mixed both serous and mucous
17
. 
Physiology of saliva 
Saliva possesses several important functions involving the oral health and 
maintaining homeostasis. It protects the oral mucosa by lubrication, helps in speech, 
perception of taste and preliminary breakdown of food particles and also acts as a 
defence against microorganisms and helps in the maintenance of enamel 
mineralization as well as inhibits demineralization
18
. 
Healthy adults produce approximately 500-1500ml of saliva per day at about 
0.5ml/min. There are lot of physiologic and pathologic conditions that affect the 
production of saliva both in quality and quantity like smell, taste, circadian rhythm, 
mental and physical state, hormones, drugs, age, oral hygiene etc
19 
. 
Salivary secretion and composition is controlled by autonomic nervous system, 
by both sympathetic and parasympathetic branches innervating the salivary glands
4
.
 
The minor salivary glands produce saliva continuously and the factors affecting the 
secretion of major salivary glands have little effect on minor glands. The parotid 
secretion is the major source of stimulated salivary secretion particularly acid-
stimulated saliva has a composition more closer to parotid secretion. The major 
composition of unstimulated whole saliva is from submandibular glands
17
.  
 
 
Composition of saliva 
The composition of saliva collected varies depending upon the particular 
mixture of secretions from the different glands through different type of stimulation. 
Salivary output and composition depend on the activity of the autonomic nervous 
system: the sympathetic system controls the serous part of the gland and the mucous 
part influenced by both sympathetic and parasympathetic system. The difference in 
stimuli and receptor action can modify the quantity, viscosity and ionic and protein 
concentrations of saliva secreted. The presence of food in the mouth can also affect 
salivary composition
19
. The terms whole saliva and/ or oral fluid denotes the fluid 
component of mouth containing the secretions from the major and minor salivary 
glands plus the gingival crevicular fluid and oral mucosa collected without stimulation 
by passive drooling or spitting
17 
. 
Salivary composition varies in relation to the serous or mucous component of 
the glands
20 
; the relative contribution of each type of gland to total unstimulated saliva 
secretion varies from 65%, 23%, 8% to 4% for submandibular, parotid, von Ebner and 
sublingual glands respectively
15 
. 
The term oral fluid and / or unstimulated whole saliva (UWS) denotes that the 
components of saliva also have a non glandular origin, Oral fluid is composed 
primarily of saliva secreted by the three major paired glands—parotid, submandibular, 
and sublingual—and numerous minor glands located throughout the oral cavity. Whole 
saliva also contains gingival crevicular fluid, sloughed oral epithelial cells, 
nasopharyngeal discharge, food debris, and bacteria and their products
4
 . 
A compositional analysis of oral fluid may be important for its implications in 
physiology, pathology and diagnosis of oral and systemic diseases. Saliva is composed 
of Inorganic, Organic, Non-protein, Protein/Polypeptide, Hormone and Lipid 
molecules
19, 21
 
Inorganic components   
Whole saliva is composed mainly of water and electrolytes
19
 (Na
+, 
K
+, 
Mg
2+
, 
Ca
2+
, Cl
-
, HCO3
-
, HPO3
2-
). 
Organic components 
This includes non-protein and lipid molecules. Eg: Uric acid, bilirubin and 
creatinine are detected in saliva. Saliva also contains glucose, amino acids, lipids like 
cholesterol and mono/diglycerides of fatty acids
19
. The content of free fatty acids and 
partial glycerides was high in saliva compared to that in blood and lymph, because of 
absence of lipase activity
21
. 
Proteins and Polypeptides in Saliva  
Saliva contains large number of proteins. Proteins derived from salivary gland 
productions are amylase, proline rich proteins (PRPS), cystatins, carbonic anhydrase, 
secretory Ig-A  and mucins
19,4
. Proteins are also from plasma leakage through gingival 
crevicular fluid like albumin, Ig-G, transferrin
19 
. Salivary proteins have wide range of 
functions, such as protection of oral tissues, defence against microorganisms, host 
immune response and in digestion. Other functions of salivary proteins are in 
remineralization of enamel, in taste perception and also in cell signalling activities
19 
 
Other proteins that are present in saliva are enzymes and enzyme inhibitors, hormones 
such as growth factors, and cytokines such as interleukin-8
22 
. 
 
 
 
Saliva as a diagnostic tool 
Interest in saliva as a diagnostic medium has increased in the past decade. 
Saliva, gingival crevicular fluid, and mucosal transudates are being used for drug 
monitoring and for the detection of various oral and systemic maladies since 1982
23
.
 
Oral fluid or whole saliva (WS) is a complex biological fluid. WS has got three 
contributors:  
1. Exocrine portion by the major and minor salivary glands with a protein 
concentration ranging between 150 to 400 mg  %, exocrine contributions from 
salivary glands are synthesized locally by specialized cells and secreted upon 
sympathetic and parasympathetic stimulation so contribute to difference in 
salivary flow rates and differences in the concentrations of salivary 
constituents.  
2. Non exocrine contributors can be either host-derived components such as  
desquamated epithelial cells, intact and remnants of blood cells, gingival fluid, 
and possibly fluid entering the oral cavity through mucosal seepage.  
3. Non host-derived components are microorganisms and food residues. Non 
 exocrine WS constituents are also derived from local sites and/or are 
 synthesized elsewhere in the body. For example, gingival fluid is a serum 
 transudate rich in protein, and enters the oral cavity through the gingival 
 crevice, it reflects the protein component in serum. Oral cavity is the portal of 
 entry to the gastrointestinal tract and also communicates with the posterior 
 nasal passage and upper respiratory tract so the whole saliva can have 
 components from these sites, and such components could point toward a 
variety of systemic diseases
4
. Thus saliva can be a useful diagnostic tool in local as 
well as systemic diseases. 
Technological developments have influenced the advances in the salivary 
diagnosis, a wide range of molecular markers in the saliva are studied and compared to 
serum levels including microbes, chemicals and immunological markers
23
 . Increasing 
interest in saliva based diagnosis and analysis is because saliva is a biological fluid and 
like blood, saliva contains many protein and RNA molecules, both of which are 
encoded by genes
24
. Blood and its components are the mainstay for laboratory 
diagnostic procedures, other biological fluids like urine and cerebrospinal fluid are 
also used for diagnosis of disease, thus saliva can also be advantageous in certain 
situations
1
. Saliva, is easy to collect, does not clot so handling is easy, low-cost storage 
and is safe for the operator and the patient
19, 24 
 
Saliva is a biologic fluid source that provides many, if not most, of the same 
molecules found in the systemic circulation. This makes saliva a potentially valuable 
fluid for the diagnosis of various systemic diseases
1
. Salivary diagnosis also has an 
advantage of use as point-of-care device which can be used at home or in a resource 
limited setting. 
Transfer of molecules from blood to saliva 
The processes by which plasma compounds can enter saliva are
19,25
 
1. Ultrafiltration:  This is through gap junctions between cells of secretory units 
(acinar and ductal cells) of salivary glands. Molecules which are lesser than 
1900 Da can enter saliva like this and their concentration in saliva is 300 – 
3000 times lower than in plasma. 
2. Transudation: Entry of plasma compounds into oral cavity, from crevicular 
fluid or from oral mucosa eg: albumin 
3. Selective transport of lipophilic molecules through passive diffusion. 
4. Active transport through protein channels, by ligand receptor binding. 
Advantage of using saliva as diagnostic tool 
Whereas blood permeates all tissues and therefore can contain molecular 
constituents arising from all organs of the body, other body fluids are more restricted 
in their association with select organs. Thus a major advantage of using other body 
fluids is that the diagnostic tests will be more specific for the biomarkers of the 
associated tissue unlike blood where all organs can shed their molecules. Saliva also 
has the advantage of being a sample that can be collected by non-invasive means and it 
also contains plasma components which enter it through active transport and passive 
diffusion. Saliva as a diagnostic medium has been closely associated with aero-
digestive system and biomolecules of systemic diseases have also been identified 
including those for endocrine function, stress or psychological state, exposure to 
infectious agents, use or metabolism of drugs or other xenobiotics, and cancers
4,26
. 
Salivary diagnostics has entered a new era with identification of human 
salivary proteome which is important for determining oral health and disease 
pathogenesis
27, 28
 and with infusion of federal funds (US) to integrate nanotechnologies 
and microfluidic engineering concepts into developing compact point-of-care devices 
for rapid analysis of this secretion
1
. As of November 2007 more than 1000 proteins 
have been identified in human saliva
24
.
   
 
Saliva, a scientific and clinical entity familiar to every oral health researcher 
and dental practitioner, has emerged as a translational and clinical commodity that has 
reached national visibility in the United States of America at the National Institutes of 
Health and the President's Office of Science and Technology. "Detecting dozens of 
diseases in a sample of saliva" was issued by President Obama as one of the 14 Grand 
Challenges for biomedical research in the 21st Century (National Economic Council, 
2010)
29
. The clinical utility of saliva as a diagnostic medium depends upon the type of 
saliva being analysed either glandular or whole saliva. Unstimulated whole saliva is 
used in majority of diagnostic purposes
1
. 
Salivary diagnosis in Dentistry 
Salivary analyses have been used in dentistry and oral diseases, to estimate the 
risk of appearance, diagnosis of disease, monitoring of disease progression and 
evaluation of therapy efficacy for caries, periodontitis, premalignant and malignant 
oral lesions, as well as infectious diseases of the oral cavity, can be assessed by 
analysing different constituents of saliva. Individuals at risk of caries can be identified 
using tests that determine saliva flow rate, saliva buffer capacity, and colonisation of 
the oral cavity by cariogenic bacteria
26
.  
Saliva as a diagnostic aid has got its use in periodontal disease diagnosis, 
prognosis and monitoring therapeutic response. Salivary analysis has been carried out 
to identify proteins, immunological markers, host cells, inflammatory mediators, 
hormones, bacteria and bacterial products
30
.  
Saliva as a diagnostic tool in systemic diseases 
Early detection of disease is important in managing a disease and reducing the 
morbidity and mortality by preventing and/or delaying the complications. To achieve 
this goal medical research is directed towards identification of molecular biomarkers 
which can help in identifying a disease at the earlier stages before complications 
develop
31
. 
A biomarker or biologic marker, according to the working group definition
32
    
“is a substance that is objectively measured and evaluated as an indicator of normal 
biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention”. These molecular biomarkers could be nucleic acids or proteins which 
can reflect the individuals physiological status and abnormality in these markers 
present in body fluids can be used for disease detection
31
.  Most systemic diseases such 
as cancer, cardiovascular, metabolic, and neurological diseases are very challenging to 
diagnose without supplementary clinical evaluation
33
. Limitations to realise early 
disease detection are
33
 
1. Lack of definitive molecular biomarkers for specific diseases 
2. Lack of an easy and inexpensive sampling method with minimal 
discomfort 
3. Lack of an accurate, easy-to-use, and portable platform to facilitate early 
disease detection 
The discovery of salivary biomarkers and the ongoing development of salivary 
diagnostic technologies is the solution to overcome these limitations. Saliva as a 
diagnostic tool is used in research and diagnostic studies of systemic diseases 
involving salivary glands and oral cavity like Sjögren syndrome. 
Sjögren’s syndrome (SS) is a systemic autoimmune disease with a variety of 
presenting symptoms which may delay its diagnosis. Sixteen WS proteins were found 
to be down-regulated and 25 WS proteins were found to be up-regulated in primary SS 
patients compared with matched healthy control subjects. These proteins reflected the 
damage of glandular cells and inflammation of the oral cavity system in patients with 
primary SS
34
. Three protein biomarkers, cathepsin D, alpha-enolase and beta-2-
microglobulin (B2M), and three mRNA biomarkers, myeloid cell nuclear 
differentiation antigen (MNDA),Guanylate binding protein 2 (GIP2) and low affinity 
IIIb receptor for the Fc fragment of IgG (FCGR3B), were significantly elevated in 
patients with pSS compared to both SLE patients and healthy controls
35
. In both the 
above mentioned studies paraffin- stimulated WS and glandular saliva specimens from 
individual major salivary glands is collected
34, 35
. The technique used to identify 
proteins and mRNA biomarkers in WS samples is Mass spectrometry, expression 
microarray profiling 
34
, western blotting or ELISA and quantitative polymerase chain 
reaction(qPCR)
35
. 
In a study to identify the significant proteins in saliva in primary sjogren 
syndrome using surface-enhanced laser desorption/ionization time-of-flight mass 
spectrometry(SELDI- TOF- MS) and two-dimensional difference gel 
electrophoresis(2D-DIGE) identified significant increases of b-2-microglobulin, 
lactoferrin, immunoglobulin (Ig) j light chain, polymeric Ig receptor, lysozyme C and 
cystatin C in all stages of SS. Two presumed proline-rich proteins, amylase and 
carbonic anhydrase VI, were reduced in the patient group
36
. 
Saliva is used as a diagnostic tool in Viral and bacterial diseases 
An oral fluid based test for detecting HIV antibodies which has got accuracy 
equivalent to serum test and much safer and easier to use has been introduced as early 
as 1997 in the United states
37, 38
. A study to analyse the utility of saliva as a diagnostic 
medium for the detection of antibodies to human immunodeficiency virus type 1 
(HIV-1) and HIV-2 under nonlaboratory conditions using a self-contained kit (Saliva z 
Strip [ST]), which combines the collection and processing, as well as the analysis, of 
the specimen. The result showed good performance for HIV -2 positive sera
39
. The 
available immunoassay kits to analyse HIV antibodies in sera were found to be 
effective to detect HIV antibodies in Oral fluid
40, 41
. 
Anti HCV antibodies were assayed in saliva of patients undergoing 
haemodialysis using Immunoassay
42
.  
Epidemiological investigation of a Hepatitis A outbreak which included 
salivary antibody testing revealed new Hepatitis A cases as well as showed anti HAV 
antibody 10 days after passive immunization
43
. Oral fluid samples were compared with 
serum samples as a specimen source for hepatitis A, B, and C virus markers. Oral fluid 
was obtained with a treated absorbent pad and tested by using existing commercial 
enzyme immunoassays with only minor modifications. Compared with serum 
sampling the sensitivity and specificity of oral sampling were 100% (51 of 51 samples) 
and 98% (46 of 47 samples) for hepatitis A virus immunoglobulin M, 100% (29 of 29 
samples) and 100% (29 of 29 samples) for hepatitis B virus surface antigen, and 100% 
(13 of 13 samples) and 100% (13 of 13 samples) for hepatitis C virus antibody, 
respectively. The decline of hepatitis A virus immunoglobulin M in oral samples was 
parallel to, though somewhat more rapid than, that of hepatitis A virus 
immunoglobulin M in serum samples
44
. 
A study using an antigen capture anti-DENV IgA (ACA) ELISA technique, 
utilising saliva from dengue confirmed patients detected dengue virus (DENV)–
specific immunoglobulin A (Ig A) early in the phase of a dengue infection, the 
sensitivity is better for( 100%) secondary infection, than primary infection( 36%)
45
. 
Helicobacter pylori was detected in saliva of patients with upper gastro 
intestinal symptoms using PCR
46,47
. The presence of antibodies to other infectious 
organisms such as Borrelia burdogferi, Shigella or Tenia Solium can also be detected 
through the saliva
48
. 
Salivary diagnostics in metabolic diseases 
  A study by Radhika S and Ranganathan K
49
 on oral candidal carriage and oral 
salivary glucose levels in Type 2 diabetes, aimed to observe that if salivary glucose 
levels monitoring can be used as a non invasive diagnostic tool for glycemic control. 
Both stimulated and unstimulated saliva was collected from Type 2 diabetes subjects 
and normal healthy controls, glucose levels determined by glucose- oxidase method, 
showed comparable saliva-plasma levels, and salivary glucose levels were 
significantly higher in diabetics than in non-diabetics. 
The discovery of salivary mRNA biomarkers using micro array analysis and 
verified by reverse transcription quantitative real time PCR has resulted in validating 
candidate  mRNA biomarkers of which 2 were upregulated and 2 were down regulated 
in type 2 diabetes mellitus (T2DM) and can be used for early detection of T2DM
50
.  
Salivary levels of Ig E, nerve growth factor, myoglobin and insulin is observed 
to be elevated in T2DM subjects and individuals with autoimmune disorders when 
compared to controls
51
. 
Salivary biomarkers in Malignancies 
Salivary soluble fragments of HER2/neu
52 
and metabolite analysis of saliva 
samples of 215 individuals with oral, pancreatic and breast cancers (n=69,18 and 30 
respectively) and  11 periodontal disease patients and 87 healthy controls identified a 
total of 57 metabolites using capillary electrophoresis time-of-flight mass spectrometry 
(CE-TOF-MS). The resultant profiles manifested relatively higher concentrations of 
most of the metabolites detected in all three cancers in comparison with those in 
people with periodontal disease and control subjects. This suggests that cancer-specific 
signatures are embedded in saliva metabolites
53
. 
Candidate protein biomarkers ( 3 proteins) in the saliva of lung cancer patients 
from 72 saliva samples of lung cancer patients and healthy controls were identified 
using Two- Dimensional Difference Gel Electrophoresis (2D-DIGE) and Mass 
spectrometry(MS) technique and these biomarkers were further validated by 
immunoassay
54
. 
Salivary transcriptomic and proteomic analysis of 10 breast cancer pations and 
10 matched controls using micro array and 2D-DIGE and comparison with 
prevalidated (previously discovered transcriptomic and proteomic biomarkers in breast 
cancer patients) samples of a different cohort revealed that there are significant 
variations in salivary molecular biomarkers between breast cancer patients and 
matched controls. Eight mRNA biomarkers and one protein biomarker, which were not 
affected by the confounding factors were identified
55
. 
Study to identify candidate protein biomarkers for early detection of oral 
squamous cell carcinoma (OSCC) from human salivary proteome resulted in 
identification of five candidate biomarkers (M2BP, MRP14, CD59, catalase, and 
profilin) detected independently in OSCC patients compared with healthy controls
56
. 
 
 
 
 
Salivary biomarkers in cardiovascular diseases  
A group of salivary biomarkers including C-reactive protein, myoglobin and 
myeloperoxidase were identified as potential diagnostic markers along with 
electrocardiogram findings in acute myocardial infarct patients
7
 
A study utilizing unstimulated WS and comparing with serum level of Acute 
Myocardial Infarct (AMI) Patients showed significant increase of creatinine 
phosphokinase levels in the first and second day of AMI, in both saliva and serum 
when compared to healthy controls, this can be useful in rapid diagnosis of AMI and 
can reduce the mortality and morbidity of myocardial infarct patients
57
. The cardiac 
specific isoform of creatinine kinase, creatinine kinase MB (CK MB) is found to be 
elevated in both unstimulated WS and serum of-care testing of acute MI
58
. 
Salivary lysozyme levels were found to be significantly increased in patients 
with oral infection, hyperglycemia and hypertension and can be a early stage 
biomarker for cardiovascular disease detection
59,60
. 
Salivary biomarkers in stress 
The National Institute for Occupational Safety and Health USA (NIOSH)  uses 
salivary IgA as a noninvasive immunologic biomarker of occupational stress
61
. An 
assessment of salivary cortisol, salivary Ig A( sIgA) and chromogranin A(CgA) among 
dental students before a academic test showed significant increase of salivary cortisol 
levels
62
. These biomarkers are also found to be increased in individuals with 
occupational stress
63
. 
Measuring of salivary alpha-amylase (sAA) and salivary cortisol (sC) appear to 
be feasible to investigate direct stress effects in relation to naturalistic traffic noise 
exposure in a laboratory setup
64
. 
Salivary biomarkers in other diseases 
  Salivary Total Cholestrol(TC), Triglycerides(TG), Low Density Lipoprotein-
Cholestrol(LDL-C) and Very Low Density Lipoprotein-Cholestrol(VLDL-C)  
concentrations were significantly high in patients with ischemic stroke when compared 
with risk and control groups. So based on this study it can be concluded that lipid 
profile can be assessed in saliva and can be used as simple, monitoring tool in stroke-
prone individuals with reasonable accuracy
65
. 
Oral fluid is used for testing the drug level concentration
66, 16
. Oral fluid, is 
used as an alternative specimen with detection time of drugs and metabolites relatively 
short and similar to blood, many drugs have analyte concentrations in the oral fluid 
that are generally proportional to those found in blood
16
.  
Levels of Salivary C-reactive protein, an inflammatory marker is compared in 
patients with Hashimoto’s thyroiditis (HT) and sub acute thyroiditis (SAT). SAT 
patients had significantly elevated salivary CRP levels compared to HT patients and 
controls. Thus saliva CRP levels can be used to serve as inflammatory markers in SAT 
patients and may aid their clinical evaluation
67
.  
Methods of saliva collection 
Oral fluid (whole saliva) is for the larger part produced and secreted by the 
various salivary glands, such as the submandibular, sublingual, and parotid glands
4
. 
Each type of salivary gland secretes a characteristic type of saliva
19
.  For example, 
sublingual saliva is very rich in mucins and contains little amylase, while parotid 
saliva, which is the main source of salivary amylase and basic proline-rich proteins, 
does not contain mucin
4
. The composition of saliva varies, depending upon whether 
salivary secretion is basal or stimulated. 
The submandibular glands are the major contributors to resting (unstimulated) 
saliva, and the parotid glands are the major contributors to stimulated saliva. The 
contribution of sublingual glands to unstimulated and stimulated whole saliva is low
15
. 
Saliva is being studied extensively and is being used for risk assessment, 
diagnosis and monitoring high-risk behavior and disease progression. The major 
disadvantage in the use of saliva for health-related purposes is the lack of 
standardization in saliva collection methods
15
. 
Several physiological and pathological conditions influence the collection of 
saliva of particular importance in clinical research and diagnostic research is the time 
of the day and duration of collection. For reliable monitoring of the functional potency 
of a salivary gland, it is recommended to collect both unstimulated and stimulated 
saliva during a period of 10 minutes for diagnostic research purposes. For further 
standardization, patients must be instructed to refrain from eating and drinking at least 
90 min prior to the test session, and to avoid swallowing and oral movements during 
collection. To minimise the effects of diurnal variation, it is advised to collect all 
saliva samples at the same, fixed time of the day
4,15
. 
Techniques for collecting glandular specific saliva 
Glandular saliva specimens from individual parotid glands were collected into 
Lashley cups (placed over the orifices of the stenson’s duct) and from the 
submandibular/sublingual glands by syringe aspiration (from the orifices of the 
Wharton’s duct, located anteriorly in the floor of the mouth), respectively34. 
Techniques for collecting unstimulated whole saliva 
The patient is advised to refrain from intake of any food or beverage (water 
exempted) one hour before the test session. Smoking, chewing gum and intake of 
coffee also are prohibited during this hour. The subject is advised to rinse his or her 
mouth several times with deionized (distilled) water and then to relax for five 
minutes
15
.  
The unstimulated WS can be collected by
25
  
1. Draining / passive drooling method. 
2. The spitting method 
3. The swabbing method 
Techniques for collecting stimulated whole saliva 
Here the salivary flow is stimulated by asking the patient to chew on a piece of 
paraffin and or by chewing on a sugar candy or by applying citric acid on the 
tongue
15,25
. 
There are companies that manufacture commercial saliva collection devices for 
diagnostic and research purposes. These include: Salimetrics oral swabs 
(http://www.salimetrics.com); Oasis Diagnostics® VerOFy® I/II; DNA_SAL™ 
(http://www.4saliva.com); OraSure Technologies OraSure HIV specimen collection 
device (http://www.orasure.com); CoZart® drugs of abuse collection devices 
(http://www.concateno.com); and the Greiner Bio-One Saliva Collection System 
(http://www.gbo.com)
26
. 
Saliva storage 
Saliva specimens, after collection, is aliquoted and frozen immediately to 
maintain the integrity of the sample, from the time of collection saliva should be kept 
in ice till final analysis. The refrigeration not only prevents degradation of saliva 
molecules but also prevents contamination by bacterial growth. Saliva contains 
bacterial protease enzymes which can degrade several salivary proteins, this can affect 
protein compound investigation
19
.  
Collection of saliva into ice cooled vials is recommended to slow down the 
activity of hydrolytic enzymes present in saliva. Further, collection in vials containing 
a cocktail of protease inhibitors, including ethylene diamine tetra acetic acid (EDTA), 
phenyl-methane-sulfonyl-fluoride (PMSF), soy bean trypsin inhibitor, and E-64, is in 
particular useful when saliva is collected for protein purification purposes to prevent 
proteolysis. Bacterial and cellular debris are directly removed after collection by 
centrifugation
4
. The method of specimen storage influences the concentration of the 
compounds to be analysed, as some salivary analytes have a very short half life and 
undergo rapid disintegration (catecholamine) and some can stay stable at room 
temperature for upto a week( Ig G)
19
 
A general approach to avoid degradation of salivary compounds
19,68
:  
1. Immediately store saliva aliquots without any processing. Specimens can often be 
stored at room temperature (when analysis is carried out immediately or in 30–90 min 
from collection), at +4 °C (when analysis is carried out in 3–6 h from collection), at 
−20 °C and better at −80 °C (when analysis is carried out days to months after 
collection). 
2. Snap-freezing of saliva in liquid nitrogen: mix each saliva aliquots with an equal 
volume of 80% glycerol in H2O, then dip the sample in liquid nitrogen. This storage 
procedure aims to inhibit the bacterial protease activity degrading some salivary 
protein compounds, such as s-IgA . 
3. Inhibition of the enzyme activity present in saliva: mix each saliva aliquot with 
enzyme inhibitors 10:1 (leupeptin, aprotinin and 4-[2-aminoethyl] benzenesulfonyl 
fluoride) 
4. Addition of sodium azide (NaN3) to saliva specimens in attempt to retard bacterial 
growth. The use of sodium azide does not influence the measurement of salivary 
markers when serum-based immunoradioassays are modified for saliva, not even if 
these methods involve separation or extraction steps. But the possible interference of 
sodium azide with horseradish peroxydase, a common component of enzyme 
immunoassays, must be taken into account. 
General considerations and limitations in saliva storage and processing
4
 
The method of collecting, storing and processing saliva should be ideal for all 
types of salivary biomarkers. The specimen collection and storage should be 
determined by the type of diagnostic research and by the stability of the salivary 
biomarker. The freezing/ thawing and prolonged storage at low temperatures affect the 
pH and viscoelasticity of the saliva and the presence of bacterial hydrolytic enzymes in 
saliva should also be taken into consideration. 
The advantage of using saliva as diagnostic tool is because of its non-invasive 
nature, and feasibility where blood sampling is not possible and its ease of use as a tool 
in resource limited settings, but saliva collection, handling and storage has its own 
limitations as it has to be centrifuged, refrigerated and/ frozen immediately to prevent 
degradation of the biomarkers. 
 
 
 
Salivary analysis 
Analysis of saliva is done either to study a group of compounds or to determine 
a single compound in oral fluid. Most often kits available for serum or plasma assay is 
modified to analyse saliva
19
. 
Salivary ionic concentrations are determined by ion selective electrodes, 
atomic absorption and spectrometric methods
19
. 
Salivary proteins structure and function are studied with lots of techniques like, 
liquid chromatography, two dimensional gel electrophoresis, capillary electrophoresis, 
mass spectrometry (MALDI-TOF), nuclear magnetic resonance, immunoassays and 
proteomic analysis of saliva
53,54,36,27
.  
The barriers to widespread implementation of saliva diagnostics derive from 
technological problems in achieving sensitivity, miniaturization, high throughput, 
automation, portability, low cost, high functionality, and speed to enable high-content 
chemical and biochemical analyses. Microfluidic systems can be designed to obtain 
and process measurements from small volumes of complex fluids, such as saliva, with 
efficiency and speed, and without the need for an expert operator. The National 
Institute of Dental and Craniofacial Research (NIDCR-USA) has initiated a concerted 
research effort in the area of saliva diagnostics. The NIDCR held a workshop on 
“Development of New Technologies for Saliva and Other Oral Fluid-Based 
Diagnostics” in September1999. In 2002 NIDCR funded a series grants to develop 
technologies to measure and analyze multiple substances in saliva at a great speed
4
.  
Salivary diagnostics has entered a new era with identification of human 
salivary proteome which is important for determining oral health and disease 
pathogenesis
27,28
 and with infusion of federal funds(US) to integrate nanotechnologies 
and microfluidic engineering concepts into developing compact point-of-care devices 
for rapid analysis of salivary secretion
1
. As of November 2007 more than 1000 
proteins have been identified in human saliva
24
 
The NIDCR funded device developing programs are
4,33
:   
 A parallel diffusion immunoassay optical based system this is capable of 
imaging several surface-linked immunoassays simultaneously. The aim of this 
system is to measure small molecule analytes such as hormones and drugs in 
whole saliva.  
 An integrated platform that includes electrochemical sensors for oral cancer 
detection. 
 Microfluidics platform, for detection of either a cytokine profile or oral 
bacteria, is based on a microchip electrophoretic immunoassay (μCEI) that 
relies on photolithographically fabricated molecular sieving gels to enrich the 
sample and a laser-induced fluorescence detector system 
 Integrated microfluidic platform for the detection of multiple pathogens based 
on an on-chip polymerase chain reaction/reverse transcriptase-polymerase 
chain reaction (PCR/RT-PCR) system. 
In addition to these microfluidics projects, the NIDCR funded salivary 
diagnostic technology development also supported development of a two bead –based 
sensor arrays. This bead-based microchip platform with fluorescence and optical 
detection capabilities has been adapted for a broad range of analyte classes including 
pH, electrolytes, metal cations, sugars, biological cofactors, toxins, proteins, 
antibodies, and oligonucleotides. The initial focus by using this is kept on cardiac risk 
assessment. 
The second bead array is based on optical fibres and its initial work focuses on 
asthma and renal patients. The seventh project focuses on the validation of a first-
generation oral chip for the identification and quantification of oral microbes by using 
high through put DNA-micro array. These systems allow miniaturization, integration, 
and multiplexing of complex functions, enabling such systems to move closer to the 
patient. 
The objective is to develop an integrated microfluidics platform where sample 
collection, processing and analyses of cellular as well as soluble analytes can be done. 
Advances in diagnostic technology promise inexpensive devices for performing real-
time analysis of a largenumber of proteins, nucleic acids, small molecules, and drugs 
in oral fluids, in the comfort of their own homes
4
. 
Cardiac biomarkers use in Acute Myocardial infaction 
Ischemic heart disease (IHD) is the leading cause of death worldwide for both 
men and women (7 million totals per year). IHD is the generic designation for a group 
of pathophysiologically related syndromes resulting from myocardial ischemia—an 
imbalance between the supply (perfusion) and demand of the heart for oxygenated 
blood 
69
. In more than 90% of cases, the cause of myocardial ischemia is reduced 
blood flow due to obstructive atherosclerotic lesions in the coronary arteries. Thus, 
IHD is often termed coronary artery disease (CAD) or coronary heart disease. 
IHD usually presents as one or more of the following clinical syndromes:  
 
•  Myocardial infarction, the most important form of IHD, in which ischemia causes 
the death of heart muscle. 
 
•  Angina pectoris, in which the ischemia is of insufficient severity to cause infarction, 
but may be a harbinger of MI. 
 
•  Chronic IHD with heart failure. 
 
•  Sudden cardiac death
 69.
 
Epidemiology 
IHD in its various forms is the leading cause of death for both males and 
females in the United States and other industrialized nations. Each year nearly 500,000 
Americans die of IHD
69
. but, the identification of major risk factors through 
population-based studies and effective control strategies combining community 
education and targeted management of high risk individuals have contributed to the 
fall in CVD mortality rates (inclusive of coronary and stroke deaths) that has been 
observed in  developed countries. At present the developing countries contribute a 
greater share to the global burden of CVD, 5.3 million deaths attributable to CVD 
occurred in the developed countries in 1990, whereas the corresponding figure for the 
developing countries ranged between 8 to 9 million (ie, a relative excess of 70%)
70.
 
The burden of cardiovascular disease is rising in India. The estimated 
prevalence of coronary heart disease is around 3–4% in rural areas and 8–10% in 
urban areas among adults older than 20 years, representing a twofold rise in rural areas 
and a six-fold rise in urban areas over the past four decades
71
. 
There are no web-based disease registries for Cardio Vascular Diseases in 
India
72
.
  
Several cross sectional studies in India shows a rising trend in coronary artery 
disease in urban India
70
. It has been estimated that India had the highest number of 
deaths (over 1.5 million) in the world due to CAD in 2002, which is expected to 
double from 1985 to 2015
72
. In India the average age for first acute myocardial 
infarction is 53 years
73
  
The INTERHEART study
74
 done as a case control study in 52 countries 
observed that younger individuals are affected more with coronary heart disease, 
attributing the risk to non-conventional and genetic factors. But in the south Asian 
population and especially India there is a increase in morbidity and mortality due to 
CHD associated with increase in conventional risk factors like diabetes and smoking, 
another important observation is that there is an increase in risk factors even among 
controls less than 60 years of age. Further, the long-term case fatality following acute 
coronary syndrome is considerably higher among Indians as compared to other 
populations
75
 this combined with lack of support mechanisms for evidence based 
treatment and follow up for AMI, results in almost 49.1 per cent higher mortality 
among the poor as compared to richest. 
 Findings from the South Asian component of INTERHEART study convey 
important messages to the health care providers and policy makers in the country as all 
these conventional risk factors for CHD are potentially modifiable and are good 
starting points for prevention 
76  
based on this study ii) early detection of persons with 
risk factors and cost-effective interventions for reducing risk; and (iii) early detection 
of persons with clinical disease and cost-effective secondary prevention measures to 
prevent complications is to be the aim of health care providers, this also implies the 
importance of identification of new markers and development of newer and cost 
effective technologies to screen the population at large for risk of CVDs especially in 
resource constrained situations. 
 
 
 
Salivary biomarkers in Cardiovascular diseases  
In this study our objective is to detect cardiac biomarkers in the saliva of 
patients admitted with signs and symptoms of acute myocardial infarction and we have 
selected a panel of biomarkers based on studies conducted in western countries
7,77, 78
. 
The National Institute of Dental and Craniofacial Research (NIDCR-USA) is 
funding a program-“Development  and validation technologies for saliva based 
diagnostics” from 2002 the aim of this program is to use nanotechnology to develop 
point of care devices and in 2006 the fund was extended for four programmes and one 
of this is headed by Dr. John McDevitt (Rice University, Houston, TX) who is 
developing salivary diagnostic device for detection of cardiac biomarkers for acute 
myocardial infarction
6
  
Currently the criteria for diagnosis of myocardial infarction is made if one of the 
following criteria is present
8
:  
1. Detection of rise and /or fall of cardiac biomarkers (preferably troponin)with at 
least one value above the 99
th
 percentile of the upper reference limit together 
with evidence of myocardial ischemia with at least one of the following: 
 Symptoms of ischemia 
 ECG changes indicative of ischemia [new ST-T changes or new left 
bundle branch block (LBBB)] 
 Development of pathological Q waves in the ECG 
 Imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality. 
Based on these criteria, a patient is diagnosed as having a ST-elevated 
myocardial infarction (STEMI), non-ST- elevated myocardial infarction (NSTEMI) or 
unstable angina. The serum biochemical markers of myocardial infarction include 
Myoglobin (MYO), Creatinine kinase-MB (CK-MB), total CK, and cardiac troponin T 
(c-TnT) and cardiac troponin I (c-TnI)
79
 .The rate and time of release of these serum 
biomarkers are dependent upon various factors and the delay in sample procurement, 
processing and analysis may be inadequate for early diagnosis and effective 
intervention. Use of saliva for diagnosis of AMI is being explored because of the 
potential possible early diagnosis, possibly in the ambulance, home or in the clinic
7 
. 
Studies with standard immunoassays showed that cardiac enzymes are present in saliva 
and levels of these enzymes were found to be elevated in patients with AMI
1,7
. 
Inflammatory markers of cardiovascular disease 
Cardiovascular disease is multifactorial and chronic inflammation is one of the 
basic mechanism for atherosclerosis, rupture of the atherosclerotic plaque and the 
subsequent thrombi being the main cause for AMI, so inflammatory markers such as c-
reactive protein
80,81
 and Myeloperoxidase
82
 are used as additional risk factors in 
determining acute cardiac events as well as to predict future risks and also for 
screening susceptible population
83,84
. 
C-Reactive protein (CRP)-Structure,Synthesis and clinical charecteristics 
CRP is a phylogenetically highly conserved plasma protein found both in 
vertebrates and invertebrates. CRP was first discovered by Oswald Avery as acute 
phase reactant in patients infected with Streptococcus pneumoniae, sera obtained from 
these patients in the acute phase of illness were found to have a protein that can 
precipitate the “C” polysaccharide in the pneumococcal cell wall85. 
CRP is a 118 KD ubiquitous protein belonging to the pentraxin family of 
proteins and is a calcium-binding protein
77
. CRP has got a lot of biological activities, it 
can activate the classical complement pathway, stimulate phagocytosis and can bind to 
immunoglobulin receptors
85
.  In humans, CRP is produced by the liver and its 
production and release regulated by cytokines such as Tumor necrosis factor-α (TNF-
α), Interleukin 1β(IL-1β) and IL-677. However extra hepatic sources of human CRP 
have been suggested in several studies and the sources include neuronal cells in 
Alzheimer’s disease, smooth muscle cells, macrophages in atherosclerotic plaques and 
adipose tissues
86
, and smooth muscle cells of diseased coronary venous bypass grafts
87
 
but these extra hepatic sources doesn’t increase the serum levels of CRP significantly, 
they are thought to be a part of the local environmental inflammatory response
85
  
CRP is produced by everyone average value in an adult is 1.5 mg/L, the levels 
are high in individuals who smoke, have hypertension, in obese individuals and levels 
tend to be lower in thin, athletic individuals; however CRP levels in an individual also 
have a genetic influence. CRP is increased in infectious conditions in acute stage of the 
infection and can be used to predict the course of infection, CRP is increased in 
chronic inflammatory diseases like Rheumatoid arthritis and is tested to monitor 
therapeutic efficiency and progress of disease
80
. 
CRP and Cardiovascular disease 
The traditional major risk factors for cardiovascular diseases are cigarette 
smoking, diabetes mellitus, hyperlipidemia and hypertension, but the absence of these 
factors does not exclude the development of cardiovascular disease. Data from studies 
by Ridker PM and Rifai N et al
88
 suggest that the C-reactive protein level is a stronger 
predictor of cardiovascular events than the LDL cholesterol level and that it adds 
prognostic information to that conveyed by the Framingham risk score. It has been 
found that patients with lower low density cholesterol one of the risk factors for 
cardiovascular disease developed CVDs and this necessitates the identification of new 
additional risk factors to predict and assess the risk of acute coronary syndromes
89, 90
. 
Studies have shown that there is an association between inflammation and 
cardiovascular disease 
83, 91, 92, 93
. Inflammation plays a central role from initiation to 
development of clinical complication in the pathogenesis of atherosclerosis from 
formation of fatty streak to plaque rupture
94.
. Studies showed that individuals with 
myocardial infarction showed a elevated serum CRP levels and the levels tend to 
remain elevated in complicated cases
95
.  The baseline CRP levels predicted the future 
risk for the development of myocardial infarction or stroke in apparently healthy 
men
96
.  Results from the women’s health study showed that eventhough other markers 
of inflammation like serum amyloid A (SAA), interleukin-6 (IL-6) and soluble 
intracellular adhesion molecule were also measured, serum CRP level has been proved 
to be a strong independent predictor of risk of cardiovascular events
97
. 
High sensitivity CRP (Hs-CRP) 
  Individuals with increased CRP levels are at 2 to 4 times higher risk of 
developing cardiovascular events. To predict risk of cardiovascular events among 
apparently healthy individuals high sensitivity assays are developed to detect CRP 
levels less than 10mg/l, the CRP levels detected by these “high-sensitivity” assays are 
called hs-CRP
80
.  
Hs-CRP assays have been developed with acceptable precisions less than 0.3 
mg/L, these previous normal ranges for CRP , predicted by hs-CRP assays seem to 
have the ability to identify CVD events
93
. 
Large population based studies like the MONICA study
98
 , the Women’s health 
study
99
  showed that there exists a dose-response relationship between the levels of hs-
CRP and risk of incidence of coronary events. Hs-CRP evaluation added to other 
established risk factors increased the predictive capacity of coronary events. Studies 
showed that through stratification, hs-CRP retains an independent association with 
incident coronary events after adjusting for age, total cholesterol, HDL cholesterol, 
smoking, body mass index, diabetes, history of hypertension, exercise level, and 
family history of coronary disease
88, 96
. Hs-CRP consistently predicts new coronary 
events in patients with unstable angina and acute myocardial infarction
93
. 
Prediction levels / Interpretation of hs-CRP assays 
Hs-CRP levels can  range between 0.3 to 8.6 mg/L for healthy men and 0.2 to 
9.1 mg/L for healthy women who are not in hormone replacement therapy and at these 
low levels hs-CRP is able predict future coronary events in apparently healthy 
people
100
. The centre for disease control (CDC) and American heart association 
(AHA) recommended the following interpretation of hs-CRP results:  
 < 1 mg/L :       Low risk 
 1to 3 mg/L:   Average risk 
 > 3 mg/L:      High risk. 
An hs-CRP level of >10 mg/L, for example, should be repeated in 2 weeks to  
allow acute inflammations to subside before retesting, two separate measurements of 
hs-CRP are adequate to classify a person’s risk level and to account for the increased 
within-individual variablility
101
 .There is absence of diurnal variation in CRP levels
102
  
Other sources for variation of CRP levels, include obesity and metabolic 
syndrome increase hs-CRP levels and loss of weight seem to coincide with reduction 
in weight
93
. 
Inflammatory markers may have greater potential as a means to augment risk 
assessment in the identification of persons who should be considered lipid-lowering, 
antiplatelet, or other cardioprotective drug therapies, as well as for increased emphasis 
on therapeutic lifestyle changes.The potential utility of hs-CRP is thus to target 
patients for primary intervention
93
.  
CRP in saliva 
In a study
103
 (n= 55) to detect Homocysteine and CRP levels in saliva of 
healthy adults and comparison with blood levels showed that when CRP 
concentrations were determined using ELISA. CRP was measurable in all saliva 
samples (range: 0.05 to 64.3 µg/L; median = 1.2 µg/L) and plasma samples (range: 
0.14 to 31.1 mg/L; median = 2.0 mg/L). Regression analysis demonstrated no 
relationship between CRP concentration in saliva and plasma (R
2
 = 0.001). 
In a study by Niveditha. L. Rao et al
67 
to estimate and compare salivary CRP 
levels between patients with Hashimato’s thyroiditis (HT, n=30) and subacute 
thyroiditis (SAT, n=15) with 20 healthy gender and age matched controls, the salivary 
CRP levels are evaluated using ELISA with enhanced sensitivity (salimetrics). The 
results showed that the salivary CRP levels are not significantly different from controls 
in HT group. SAT patients had significantly increased salivary CRP levels when 
compared to both HT and control group and this increase reflects the presence of 
inflammatory process in SAT and salivary CRP may aid in diagnosis and clinical 
evaluation of SAT. 
In a Finland study
59
 done utilizing cross-sectional data from 250 coronary 
artery disease (CAD) and 250 non- CAD patients, to determine the association of 
salivary lysozyme (SLZ) and CRP with metabolic syndrome (metS) which is a pro 
inflammatory state, salivary CRP was determined by  high-sensitivity 
immunoturbidometry assay. Salivary CRP levels were distinctly higher in the CAD 
group than in the non-CAD group regardless of metS status and CRP was not 
significantly associated with metS independent of CRP. 
In a paper published by Christadoudiles N et al
77
.  a novel method was used to 
detect the CRP in human saliva this newer lab-on-chip technique  based on electronic 
taste chip (ETC) approach showed higher sensitivity than the traditional hs-CRP 
ELISA, because of the increased surface area of the micro beads for more 
antigen/antibody interaction, and was able to detect CRP levels as low as 10 
picograms/ml even with 1000 fold of dilution of saliva. This study showed that higher 
values of CRP were seen in subjects with chronic periodontal disease. 
A feasibility study by Floriano PN et al
7
. in the use of saliva based nano-
biochip for acute myocardial infarction. A Luminex and lab-on-a-chip methods was 
used to assay 21 proteins in serum and unstimulated whole saliva procured from 41 
AMI patients within 48 h of chest pain onset and from 43 apparently healthy controls.. 
The results showed significant difference in concentrations of cardiac biomarkers both 
traditional (Creatinine kinase, myoglobin, cardiac troponin I) and novel (CRP, 
Myeloperoxidase) in subjects with AMI and healthy controls.  
Foley JD et al
104
 conducted a study to determine the ability of the salivary 
biomarkers to identify different aspects of myocardial necrosis. In this study serum and 
UWS was procured from patients undergoing alcohol septal ablation (ASA) for 
treatment of hypertrophic cardiomyopathy at baseline and incremental time points 
post-ASA. Seven biomarkers related to myocardial damage, inflammation, and tissues 
remodelling using immunosorbent assays were analyzed. Levels were compared with 
baseline and levels observed in 97 healthy controls. The results showed biomarkers of 
myocardial damage and inflammation (ie, troponin I, creatine kinase-MB, myoglobin, 
C-reactive protein) rose in serum upto 2- to 812-fold after ASA .Significant elevations 
of 2.0- to 3.5-fold were observed with CRP and troponin I in saliva. Significant 
correlations between levels in serum and saliva were observed for C-reactive protein, 
matrix metalloproteinase-9, and myeloperoxidase. These data suggest that select 
salivary biomarkers can reflect the changes in myocardial necrosis that is caused by 
ASA which occurs during and after the treatment.  
A study by Punyadeera C et al
78
  using a homogeneous bead based assay to 
detect CRP levels in human saliva was done to establish a saliva CRP reference range 
and to demonstrate the clinical utility of salivary CRP levels in assessing the coronary 
events in a primary health care setting. Saliva from cardiac patients and healthy 
controls were assessed by means of a one step optimized assay, and the results showed 
a positive correlation between serum and saliva samples and the salivary CRP levels 
from healthy volunteers and cardiac patients were distinguishable.  
Immunoturbidimetric assay for quantitative detection of Hs-CRP 
Different methods for quantifying CRP in serum have been used. 
Immunoturbidimetric (IT) assay is used to detect CRP through high sensitive assay. 
This technique measures increased turbidity resulting from antigen-antibody 
complexes. The technique uses ready to use liquid reagents and a chemical analyser 
which can measure the absorbance values and results are obtained within 20 minutes. 
Robert et al
105
 evaluated nine hs-CRP assays (7- IT; 1- Immunonephelometric 
(IN); and 1- Immunoluminometric (IL) ) from nine different manufacturers  for limit 
of detection, linearity, precision, prozone effect, and comparability with samples from 
388 apparently healthy individuals. Of the nine methods evaluated, seven  had  limits 
of detection < 0.2 mg/L ,therefore the paper concluded that hs-CRP assays  has  to be 
standardized for concentrations of  0.2–10 mg/L so that results obtained in large 
population studies can be applied to individual patients cut-off-points and with 
establishment of standardization, hs-CRP assays can provide useful data for coronary 
risk stratification in apparently healthy individuals. 
In a study by Kusnierz-Cabala B et al
106
, which compared hs-CRP assays using 
nephelometry and immunoturbidimetric techniques to evaluate the serum CRP 
concentrations to assess the cardiovascular risk in chronic metabolic diseases. The 
results were similar with techniques and it was concluded that turbidimetric high 
sensitive CRP assays can properly classify CRP-related prediction of chronic 
metabolic diseases with special consideration on cardiovascular risk. 
MYOGLOBIN 
Functions and role in clinical diagnosis 
Myoglobin is a heme protein (Molecular weight = 17.8Kda) and helps in 
transport of oxygen within muscle cells.Myoglobin constitutes about 2 % of muscle 
protein in both cardiac and skeletal muscle. Because of its low molecular weight, 
myoglobin is rapidly released into the circulation and is the early marker to rise after 
an AMI and it was the first serum cardiac marker that was not an enzyme or an 
isoenzyme.  
Serum myoglobin levels are elevated in conditions unrelated to AMI, such as 
skeletal muscle, neuromuscular disorders, renal failure, intramuscular injection, 
strenuous exercise and in presence of various toxins and drugs Very little free 
myoglobin (12-100ng/ml) circulates as result of natural protein turnover.  
During the course of a myocardial infarction, myoglobin escapes from the 
ischaemic cardiac muscle, and the myoglobin levels increase measurably above 
baseline within 2-4 hours post-infarct, peaking at 9-12 hours, and returning to baseline 
within 24-36 hours It is rapidly removed from circulation, filtered through the 
glomerular membrane of the kidney, and excreted in the urine. Rapid kinetic of 
myoglobin serum level is important for its utility as marker for reperfusion and re-
infarction diagnosis
12,107
.  
In a study by McComb JM et al 1984
108
, to compare the sensitivity and 
specificity of the serum levels of creatinine kinase (CK) and myoglobin to diagnose 
AMI, it was found  that the serum myoglobin concentration was raised (> 85g/l) in 
25% of patients at one hour of onset of symptoms and  in 89% of patients at four 
hours, compared to 25% and 56% of serum CK levels respectively, within 12 hours the 
myoglobin values peaked in 83% of the patients compared to only 14% of CK and the 
myoglobin values fell to normal within 36 hours in 36 % while the CK values came 
back to normal in only 4 % of patients at 36 hours. This study showed that a single 
measurement of serum myoglobin concentration at 6 hours from onset of symptoms 
predicts diagnosis of suspected myocardial infarction with a sensitivity of 93% and 
specificity of 89% . 
In a study
109
 to evaluate the value of myoglobin, CK-MB mass and TroponinT to 
rule out AMI in the emergency department, it was found that myoglobin is the earliest 
marker and has got 89% negative predictive value (NPV) after 4 hours of onset of 
symptoms and this is significantly higher than the NPVs of CK-MB mass and 
TroponinT. Therefore myoglobin is a better marker to rule out AMI in the emergency 
room from 3 to 6 hours of onset of symptoms. 
A study by McCord J et al
110
 evaluated a serum multimarker stratergy 
including Creatinie kinase –MB (CK-MB), Myoglobin and cardiac troponin I using a 
point-of-care quantitative detection to rule out AMI in ≤ 3 hours. In patients admitted 
to the emergency department with signs and symptoms of AMI, serum was collected 
from patients with non diagnostic ECGs, and the CK-MB, troponin I, and myoglobin 
levels were measured with a point-of-care device at presentation and at 90 minutes, 3 
hours, and 9 hours. The results of this study concluded that AMI can be “ruled out” or 
“ruled in” more rapidly by use of a combination of normal cTnI and myoglobin values 
done at 0 and 90 minutes after admission in the emergency department. 
Myoglobin in saliva 
In a study
51
 to evaluate the elevated levels of salivary proteins like 
immunoglobulin E, nerve growth factor and myoglobulin by means of ELISA from 
unstimulated whole saliva collected from patients with type 2 diabetes mellitus and 
autoimmune diseases and normal controls, it is found that the salivary levels of the 
above mentioned protein markers were raised in type 2 diabetes and other diseased 
patients than in normal controls. 
In a poster presented by Yashari J et al
111
 at the AADR annual meet 2010, the 
relationship between salivary and serum biomarkers in AMI-patients and non-AMI 
controls to determine the ability of the salivary and serum biomarkers to discriminate 
between different types (STEMI and NSTEMI) of AMI was studied. In this study 
(UWS) whole saliva and serum were obtained from controls and AMI patients within 
72 hours of chest pain onset. Levels of brain-natriuretic peptide (BNP), troponin I 
(TnI), creatine kinase-MB (CK-MB), myoglobin (MYO) and 13 Luminex-analyzed 
biomarkers relevant to cardiovascular disease were determined in the serum and saliva. 
The results showed that MYO levels in UWS were significantly different within 48 
hours of chest pain onset in AMI patients compared with non-AMI patients, and UWS 
MYO levels correlated positively (r=0.55) with serum concentrations (p<0.0001). 
Significant differences in biomarker profiles between ST elevated MI and non-ST 
elevated MI were observed in serum, but not UWS. From these findings it can be 
suggested that that select UWS biomarkers may be useful for aiding in the 
identification of AMI. 
C-reactive protein and Myoglobin in diagnosis of AMI: 
A study
112
 was done to investigate the sensitivity and specificity of myoglobin 
to diagnose MI in emergency room and also to investigate the relationship of serum 
CRP and MYO together in early diagnosis of MI. Samples were collected on 
admission and after 6 hours. The results showed that the serum concentration of MYO 
was higher in all MI patients with 100% sensitivity but it was also higher in 20% of 
normal controls making the specificity 78%, the serum CRP levels were also higher in 
MI patients than normal controls. The results of the study showed that the MYO levels 
should assessed atleast twice once on admission and one after 6 hours and the CRP 
levels when assessed on the first day of admission render a faster and better diagnoses. 
CRP and MYO in saliva 
Floriano PN et al
7
 observed that the saliva-based biomarker panel of C-reactive 
protein, myoglobin, and myeloperoxidase exhibited significant diagnostic capability 
and in conjunction with ECG yielded strong screening capacity for AMI, so the saliva 
based nano- bio chip can be used as an adjunct in diagnosis of AMI along with ECG in 
prehospital stages. 
Yashari J et al
111
 in their study using UWS for evaluation of salivary 
biomarkers in AMI found that, UWS levels of MYO and CRP were raised in AMI 
patients and showed positive correlation with serum concentrations (r=0.55 and 0.37 
respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              
 
Results 
 
Out of the 30 samples collected from Group I subjects, only 28 samples were 
used. The 2 samples were excluded because the 24-48hours and 48-72hours sample 
could not be collected as the patients developed pneumonia. Among the 28 samples for 
4 samples the 48-72 hours sample could not be collected because the patient was 
shifted to a different medical facility. Only 24 subjects had all three saliva samples. 
Out of the 15 samples collected from Group II A subjects, only 14 samples 
were used, one sample was excluded because of the viscosity detected at the time of 
analysis. Out of the 14 samples used in Group II A 2 samples were not included in the 
results as they showed abnormal (outliers) values  
Out of the 15 samples collected from Group II B subjects, only 13 samples 
were used, 2 samples were excluded because of sample contamination detected at the 
time of analysis. 
The study population consists of 3 groups, Group I – Acute myocardial infarct 
patients (n=28) Group II A- controls with periodontitis (n=12) and Group II B- 
apparently healthy controls without periodontitis (n=13). In group I 60.7% (n=17, 
males=17, females=0) had ST segment elevated myocardial infarction (STEMI) and 
30.9% (n=11, males=6, females=5) had Non-ST segment elevated myocardial 
infarction (NSTEMI). 
Gender distribution among study groups (Table 1; Graph 1) 
The distribution of gender among the study population was 82.1% of males 
(n=23) and 17.9% of females (n=5) in Group I, 50% males (n=6) & 50% females 
(n=6) in Group II A and 30.8% males (n=4) and 69.2% of females (n=9) in Group II B. 
Age distribution among study groups (Table 2; Graph 2) 
The mean age in Group I was 54.8 ± 9.6 (males=56.1 ± 9, females=48.8 ± 
11.1) with an age range of 35-71 years. The mean age in Group II A was 47.3 ± 9.9 
(males=50 ± 11.4, females= 44.6 ± 9.8) with an age range of 35 - 63 years. The mean 
age in Group II B was 44.6 ± 9.6 (males=50.7 ± 11.5, females=41.8 ± 7.9) with an age 
range of 34 - 65 years.  
Prevalence of habits among the study groups (Table 3; Graph 3) 
In group I 82.1 % (n=23) of individuals had no habit of tobacco smoking or 
drinking alcohol, 14.3 % (n=4) had the habit of cigarette smoking and 3.6 % (n=1) had 
the habit of drinking alcohol. In group II A 75% of individuals had no habit of tobacco 
smoking or drinking alcohol and 25% had the habit of smoking cigarettes. In group II 
B none had the habit of tobacco smoking or drinking alcohol. The prevalence of habits 
are not statistically significant among the study groups (P=0.533) 
Expression of salivary Hs-CRP levels (mg/L) between study groups (Tables 4 to 8; 
Graphs 4 to 6)  
The salivary hs-CRP levels are higher in Group I when compared to Group II 
A and Group II B in samples collected at 6-12 hours (P=0.255), 24- 48 hours 
(P=0.677) and 48- 72 hours (P=0.266). Multiple comparisons between groups I, II A, 
II B with ANOVA followed by Tukey HSD didn’t show any statistical significant 
difference between groups in salivary hs-CRP expression. Comparison between Group 
I and Group II (Gp II A+ II B) by t-Test didn’t show any statistically significant 
difference in salivary expression level of hs-CRP in samples collected at 6-12hours 
(P=0.157), 24-48hours (P=0.527) and 48-72hours (P=0.177). There is no statistically 
significant difference among the salivary hs-CRP levels collected at 6-12hours, 24- 
48hours and 48-72hours from patients in Group I (P=0.113). Salivary hs-CRP levels 
between STEMI  and NSTEMI  patients  in Group I at samples collected at 6-12hours 
(P=0.132), 24- 48 hours(P=0.241) and 48-72 hours(P=0.379) are not statistically 
significant. 
In group I out of the 28 subjects from whom the samples were collected the 48 
-72 hours sample was not collected from subjects 11, 15, 16 and 28 and for subject 14 
the 6 -12 hours sample was not sufficient. (Graph 4). All the saliva samples showed 
values of hs-CRP in the range of 0.2 mg/L to 1.47mg/L. Among the 28 samples, 
sample 4 and 21 showed increased expression (1.47mg/L and 1.45mg/L respectively) 
in the samples collected at 24- 48 hours compared to samples collected at 6-12hours 
(0.76mg/L and 0.65mg/L) and samples collected at 48 -72 hours (0.59mg/L and 
0.6mg/L) samples 9 and 27 showed increased expression (1.28mg/L) in samples 
collected at 48 – 72 hours compared to samples collected at 6-12hours (0.44mg/L and 
0.15mg/L respectively) and samples collected at 24-48 hours (0.46mg/L and 
0.79mg/L).  
In group II A all the 12 samples showed salivary hs-CRP expression the values 
ranged from 0.24 mg/L to 0.69 mg/L (graph 5). In group II B all the 13 samples 
showed salivary hs-CRP expression the values ranged from 0.35mg/L to 0.87mg/L. 
(Graph 6) 
Expression of salivary Myoglobin (ng/ml) between groups (Tables 9-13; Graphs 
7-9) 
Salivary Myoglobin levels are higher in Group II B than Group II A, which 
was in turn higher than the Group I in samples collected at 6 -12 hours (P=0.126) and 
this difference was statistically significant in samples collected at 24- 48 hours 
(P=0.013) and  48-72 hours (P=0.022). Multiple comparisons between Group I, II A 
and II B with Tukey HSD showed no statistically significant difference in salivary 
myoglobin expression in samples collected at 6-12 hours. 
On comparison between samples collected at 24-48hours in Group I subjects 
and Group II A and II B, there is no difference in the salivary myoglobin expression 
between Group I and II A. The salivary myoglobin expression showed a significant 
increase in Group II B than in Group I (P=0.010).  
On comparison between samples collected at 48-72hours in Group I subjects 
and Group II A and II B, there is no difference in the salivary myoglobin expression 
between Group I and II A.  The salivary myoglobin expression showed a significant 
increase in Group II B than in Group I (P=0.017).  
t-test was done to compare the salivary myoglobin expression between Group I 
and Group II (Group II A + II B), there is no difference in samples collected at 6-
12hours. The expression levels showed significant increase  in samples collected at 24-
48hours (P=0.009) and 48-72hours (P=0.015), the expression higher in Group II than 
in Group I. 
Expression of salivary myoglobin level within Group I showed a significant 
increase in the samples collected at 6 - 12 hours (P=0.018) than samples collected at 
24 - 48 hours and 48 - 72hours.   
Expression of salivary myoglobin levels between STEMI and NSTEMI 
patients in Group I in samples collected at 6 -12 hours was significantly increased 
(P=0.043), the expression being higher in NSTEMI patients and not significant in 
samples collected at 24 - 48hours (P=0.553) and 48 - 72hours sample (P=0.545). 
In group I out of the 28 subjects from whom the samples were collected, the 48 
-72 hours sample was not collected from subjects 11, 15, 16 and 28. Out of the 28 
samples, samples 4, 6, 7, 8,9, 11, 13, 14, 15, 17, 18, 20, 21, 23, 24, 26 & 28 expressed 
negative (below the absorbance levels) values , in subject 6 and 17 all the 3 samples 
collected at 6 -12 hours, 24- 48 hours and 48 – 72 hours expressed negative values and 
in subject 11, 15 and 28 both the samples collected at 6 -12 hours and 24-48 hours 
showed negative values (Graph 7). Out of the 28 samples 14 expressed increased 
salivary myoglobin values in the samples collected at 6 – 12 hours compared to 
samples collected at 24 – 48 hours and 48 – 72 hours, 2 samples showed a mild 
increase in values in the sample collected at 24- 48 hours compared to 6-12hours and 
48- 72 hours sample and 2 samples showed increase in myoglobin expression in 
sample collected at 48 – 72 hours. The salivary myoglobin values ranged from 0.154 
ng/ml to 10.23 ng/ml.  
In group II A out of the 12 samples, samples 5 and 10 showed negative values 
for salivary myoglobin expression. The values ranged from 0.208 ng/ml to 10.23 ng/ml 
(Graph 8). In group II B out of the 13 samples, samples 3 and 12 showed negative 
values salivary myoglobin expression. The values ranged from 0.917ng/ml to 
11.63ng/ml. (Graph 9). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tables and Graphs 
     
 
 Table 1 
Gender distribution among study groups 
 
Study Groups Male Female 
Group I 
(n = 28) 
n = 23 
82.1% 
n = 5 
17.9% 
Group II A 
(n = 12) 
n = 6 
50 % 
n = 6 
50 % 
Group II B 
(n = 13) 
n = 4 
30.8% 
n = 9 
69.2% 
 
 
 
 
 
 
 
Graph 1 
Gender distribution among study groups 
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Table 2 
Age distribution (in years) among study groups 
  
 
Study Groups Overall Mean Age Mean Age of Males 
Mean Age of 
Females 
Group I 
(n = 28, M = 23, 
F=5) 
54.8 ± 9.6 56.1 ± 9 48.8 ± 11.1 
Group II A 
(n = 12, M = 6, 
F=6) 
47.3 ± 9.9 50 ± 11.4 44.6 ± 9.8 
Group II B 
(n = 13, M = 4, 
F=9) 
44.6 ± 9.6 50.7 ± 11.5 41.8 ± 7.9 
 
 
 
Graph 2 
Distribution of Age (in years) among study groups 
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 Table 3 
Prevalence of habits among study groups 
 
Study Groups No Habit Smoking Drinking 
Group I 
(n = 28) 
n = 23 
82.1% 
n = 4 
14.3% 
n = 1 
3.6% 
Group II A 
(n = 12 ) 
n = 9 
75% 
n = 3 
25% 
n=0 
Group II B 
(n = 13) 
n = 13 
100% 
n = 0 n = 0 
 
 
 
 
Graph 3  
Prevalence of habits among study groups 
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Table 4 
Expression of salivary hs-CRP (mg/L) between groups 
 
  n Mean 
Std. 
Deviation 
 
P value 
Saliva-HS-
CRP(mg/L)  6-12hrs 
Group I 27
* 
.67037 .228397 0.255 
 Group II A 12 .56083 .130346  
 Group II B 13 .62692 .132249  
      
Saliva-HS-
CRP(mg/L)          
24-48hrs 
Group I 28 .62500 .277936 0.677 
 Group II A 12 .56083 .130346  
 Group II B 13 .62692 .132249  
      
Saliva-HS-
CRP(mg/L)          
48- 72hrs 
Group I 24
** 
.66500 .215790 0.266 
 Group II A 12 .56083 .130346  
 Group II B 13 .62692 .132249  
 
 
*- Sample collected at 6-12 hours was not used as it was not sufficient. 
 
**- 3
rd
 sample at 48-72 hours could not be collected 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 4 
Salivary hs-CRP expression (mg/L) in Group I 
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Graph 5  
Salivary hs-CRP expression (mg/L) in Group II A 
 
 
 
 
 
Graph 6  
Salivary hs-CRP expression (mg/L) in Group II B 
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Study subjects (n=13) 
Table 5 
Multiple comparison of salivary hs-CRP expression between Group I, II A and II B 
 
 
Dependent Variable (I) Group (J) Group 
Mean 
Difference 
(I-J) 
P  value 
Saliva-hs-
CRP(mg/L)             
6 -12hrs 
Group I Group II B .04345 0.776 
  Group II A .10954 0.227 
 Group II B Group I -.04345 0.776 
  Group II A .06609 0.660 
 Group II A Group I -.10954 0.227 
  Group II B -.06609 0.660 
Saliva-hs-
CRP(mg/L)            
24 – 48hrs 
Group I Group II B -.00192 1.000 
  Group II A .06417 0.683 
 Group II B Group I .00192 1.000 
  Group II A .06609 0.740 
 Group II A Group I -.06417 0.683 
  Group II B -.06609 0.740 
Saliva-hs-
CRP(mg/L)          
48- 72hrs 
Group I Group II B .03808 0.810 
  Group II A .10417 0.236 
 Group II B Group I -.03808 0.810 
  Group II A .06609 0.628 
 Group II A Group I -.10417 0.236 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6 
Expression of salivary hs-CRP between Group I and Group II (II A + II B) 
 
 Group n Mean 
Std. 
Deviation 
 
 
P value 
Saliva-hs-
CRP(mg/L)6 -
12hrs 
Group I 27* .67037 .228397 0.157 
 Group II 25 .59520 .132920  
Saliva-hs-
CRP(mg/L)24 
– 48hrs 
Group I 28 .62500 .277936 0.627 
 Group II 25 .59520 .132920  
Saliva-hs-
CRP(mg/L)48 
– 72hrs 
Group I 24** .66500 .215790 0.177 
 Group II 25 .59520 .132920  
 
*- Sample collected at 6-12 hours was not used as it was not sufficient. 
 
**- 3
rd
 sample at 48-72 hours could not be collected 
 
 
 
 
Table 7 
Expression of salivary hs-CRP level within Group I 
 
 n* Mean Std. Deviation 
P value Saliva-hs-CRP(mg/L) 6-
12hrs 
23 .68870 .235165 
Saliva-hs-CRP(mg/L) 24- 
48hrs 
23 .65174 .296367 
0.113 
Saliva-hs-CRP(mg/L) 48- 
72hrs 
23 .68087 .205822 
 
*- Only cases with all three values were included.  
 
 
 
 
 
 
 
 
 
 Table 8 
Comparison of hs-CRP expression in saliva between  
STEMI and NSTEMI patients in Group I 
 
 ECG n Mean Std.deviation P value 
      
Saliva-hs-
CRP(mg/L)  
6 -12hrs 
STEMI 16* .72563 .240582 0.132 
N STEMI 11 .59000 .191885  
Saliva-hs-
CRP(mg/L) 
24 – 48hrs 
STEMI 17 .57471 .266649 0.241 
N STEMI 11 .70273 .289589  
Saliva-hs-
CRP(mg/L) 
48 – 72hrs 
STEMI 14** .63143 .222982 0.379 
N STEMI 10** .71200 .207300  
STEMI: ST elevated myocardial infarction, NSTEMI: Non-ST elevated myocardial infarction 
*- Sample collected at 6-12 hours was not used as it was not sufficient. 
**- The 3
rd
 sample at 48-72 hours could not be collected 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9 
Expression of salivary Myoglobin (ng/ml) between groups 
 
  n Mean Std.deviation P  value 
Saliva-
MYO(ng/ml) 
6 -12hrs 
Group I 28 1.43589 3.615417 0.126 
 Group II A 12 1.67508 3.718136  
 Group II B 13 4.40246 6.134160  
Saliva-
MYO(ng/ml) 
24- 48hrs 
Group I 28 -.60568
# 
4.713742 0.013
* 
 Group II A 12 1.67508 3.718136  
 Group II B 13 4.40246 6.134160  
      
Saliva-
MYO(ng/ml) 
48- 72hrs 
Group I 24** -.64842
# 
5.117443 0.022
* 
 Group II A 12 1.67508 3.718136  
 Group II B 13 4.40246 6.134160  
      
* P value is significant at the level of 5%, P<0.05 
# The mean values are negative as 60% of the samples showed negative (below the 
absorbance level) values. 
**- 3
rd
 sample at 48-72 hours could not be collected 
 
 
 
 
 
 
 
 
 
 
 
 
 Graph 7  
Salivary myoglobin expression (ng/ml) in Group I 
  
 
Graph 8  
Salivary myoglobin expression (ng/ml) in Group II A 
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Study subjects (n=12) 
  
 
 
Graph 9  
Salivary myoglobin expression (ng/ml) in Group II B
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Study subjects (n=13) 
Table 10 
Multiple comparison of salivary Myoglobin levels among groups 
 
Dependent Variable (I) Group (J) Group 
Mean 
Difference 
(I-J) 
P  value 
Saliva-MYO(ng/ml) 
6-12hrs 
Group I Group II B -2.96657 0.118 
  Group II A -.23919 0.986 
 Group II B Group I 2.96657 0.118 
  Group II A 2.72738 0.273 
 Group II A Group I .23919 0.986 
  Group II B -2.72738 0.273 
Saliva-MYO(ng/ml) 
24- 48hrs 
Group I Group II B -5.00814 0.010
* 
  Group II A -2.28076 0.376 
 Group II B Group I 5.00814 0.010 
  Group II A 2.72738 0.354 
 Group II A Group I 2.28076 0.376 
  Group II B -2.72738 0.354 
Saliva-MYO(ng/ml) 
48- 72hrs 
Group I Group II B -5.05088 0.017
* 
  Group II A -2.32350 0.412 
 Group II B Group I 5.05088 0.017 
  Group II A 2.72738 0.386 
 Group II A Group I 2.32350 0.412 
  Group II B -2.72738 0.386 
 * P value is significant at the level of 5%, P<0.05 
Table 11 
Expression of salivary Myoglobin levels between Group I and Group II 
(II A+ II B) 
 
 Group n Mean 
Std. 
Deviation 
 
 
P value 
Saliva-
MYO(ng/ml) – 
6-12hrs 
Group I 28 1.43589 3.615417 0.180 
 Group II 25 3.09332 5.204252  
Saliva-
MYO(ng/ml) – 
24-48hrs 
Group I 28 -.60568 4.713742 0.009
* 
 Group II 25 3.09332 5.204252  
Saliva-
MYO(ng/ml) – 
48-72hrs 
Group I 24** -.64842 5.117443 0.015
* 
 Group II 25 3.09332 5.204252  
 
**- 3
rd
 sample at 48-72 hours could not be collected 
 
 
 
 
 
Table 12 
Expression of salivary Myoglobin level within Group I 
 
 n** Mean 
Std. 
Deviation 
Minimu
m 
Maximu
m 
 
 
P=0.018* 
Saliva-MYO(ng/ml) 
6-12hrs 
24
 
1.82746 3.717651 -5.740 9.346 
Saliva-MYO(ng/ml) 
24-48hrs 
24
 
-.27575 4.933014 -15.700 8.755 
Saliva-MYO(ng/ml) 
48-72hrs 
24
 
-.64842 5.117443 -16.000 10.230 
 
* P value is significant at the level of 5%, P<0.05 
 
**- Only cases with all three sample values were included.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 13 
Comparison of Myoglobin expression in saliva between STEMI and 
NSTEMI  patients in Group I 
 
* P value is significant at the level of 5%, P<0.05 
 
#
- Sample collected at 6-12 hours was not used as it was not sufficient. 
 
**- 3
rd
 sample at 48-72 hours could not be collected 
 
 
 
 
 
 ECG n Mean 
Std. 
Deviation 
 
P value 
Saliva-
MYO(ng/ml) – 
6-12hrs 
STEMI 17
#
 .33794 3.401416 0.043
* 
 N STEMI 11 3.13273 3.400649  
Saliva-
MYO(ng/ml) – 
24-48hrs 
STEMI 17 -1.04171 5.117058 0.553 
 N STEMI 11 .06818 4.156289  
Saliva-
MYO(ng/ml) – 
48-72hrs 
STEMI 14** -1.19843 6.224650 0.545 
 N STEMI 10** .12160 3.135162  
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Fig 1. CS 400 Auto analyser – Hs-CRP IT assay            Fig 2. Micro-centrifuge 
        tube (1.5ml) 
 
 
 
 
 
 
      
      
Fig 3. Micropipettes and pipette tips                Fig 4. Myoglobin ELISA reagents 
 
 
 
 
  
 
 
 
Fig 6. ELISA-Auto washer 
 
 
 
 
 
 
 
 
 
 
Fig 5. ELISA-  microtitre well reader 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       
Discussion 
     
 
 
 
This study was done to evaluate saliva as a diagnostic tool in early diagnosis of 
acute myocardial infarction (AMI) by quantitatively detecting the levels of C-reactive 
protein by means of a high-sensitivity immunoturbidimetric assay and Myoglobin by 
ELISA and to compare it with non-AMI controls.  
Human saliva contains proteins that are present in serum and its collection is 
non-invasive which makes it an ideal tool for large patient screening and diagnosis
1,78
. 
Myocardial infarction is a major cause of death and disability worldwide in 
both gender in the adult age group of 15-59 years
69, 8,73
. Cross-sectional studies in 
India have shown a rising trend in Coronary artery disease (CAD) in the past 30 years 
and a higher prevalence is seen in South India
72, 73
.  
The prevention and treatment of CAD requires a highly responsive healthcare 
system, which includes use of novel and newer biomarkers and techniques which can 
aid in screening, early diagnosis and predict future cardiovascular events in apparently 
healthy people.  
CRP is an acute phase reactant which is released in circulation during the 
inflammatory and infectious conditions. CRP levels when assessed by high-sensitive 
assays helped in detection of future risk of cardiovascular diseases in apparently 
healthy individuals and also predicts prognosis of AMI patients
80
.  
Myoglobin is a heme protein and is a non-specific cardiac biomarker which is 
released earlier in case of AMI and is useful in early diagnosis of AMI patients in the 
emergency room especially in NSTEMI patients.  
To our knowledge this is one of the first studies in India utilising UWS to 
evaluate cardiac biomarkers in AMI patients. 
In our study there was a male preponderance in group I 82.1% (n=23) 
compared to 17.9 % of female (n=5) which is similar to other study
57
 done in AMI and 
non-AMI controls to evaluate CK-MB levels in UWS. This gender distribution is also 
similar to the demographic profile of CAD patients in Indian population published by 
Gupta S et al
113
. 
Our study showed an increase in percentage of STEMI patients (60.7%) 
compared to NSTEMI (30.9%) patients which is in concurrence with the findings of 
Gupta S et al
113 
(75.4% and 24.6% respectively). 
In our study the age range of patients with AMI in group I is 35-71 years and 
the overall mean age is 54.8 years which is in concordance with the findings published 
in a review by Indian council of medical research
73
. 
In our study 3 serial collections of UWS was done in patients admitted to the 
cardiac care unit, first sample at 6 -12 hours, second sample at 24- 48 hours and third 
sample at 48 -72 hours was collected after the onset of signs and symptoms of AMI, to 
investigate the rise and fall of CRP and myoglobin and to evaluate the utility of UWS 
as a useful diagnostic tool in early diagnosis of AMI. This serial collection of UWS is 
similar to other studies done in saliva and serum to evaluate cardiac biomarkers 
57,104
 
as opposed to studies which relied on one step collection of saliva to evaluate 
biomarkers in patients with CAD
7, 78
. 
The collected UWS samples were centrifuged and the supernatant was 
separated and stored in aliquots at -70 degree Celsius till analysis and this is in 
concordance with other studies that investigated cardiac biomarkers in UWS
7,77,57
. 
The results of our study from analysing UWS for CRP using a high-sensitive 
immunoturbidimetric assay showed that hs-CRP expression is seen in all the samples 
collected from AMI patients (group I) and non-AMI controls (group II A + II B) in the 
range of 0.2 to 1.47mg/L, there was no statistically significant difference in salivary 
hs-CRP expression among the study groups but there is an increased expression (not 
statistically significant-Table 4) in the group I (AMI patients) population in all the 3 
samples collected at different time period compared to non-AMI controls concurrent 
with the findings that CRP levels are significantly (P<0.01) increased in patients with 
AMI than normal individuals
8,78
. Among group II which is subdivided into II A- 
controls with periodontitis and II B - normal healthy controls without periodontitis 
there was no statistically significant difference in salivary hs-CRP expression and the 
expression levels were not higher in controls with periodontitis as compared to normal 
controls, this finding was different from the previous study findings that showed that 
hs-CRP levels are higher in individuals with periodontitis
77
.  
The hs-CRP levels in group I did not show any difference in saliva collected at 
different time periods contrary to increase seen in serum CRP levels at 36-48hours 
from the baseline value reported by Habib et al
114
 and in a study similar to ours the 
CRP levels were found to be increased after alcohol septal ablation upto 4 fold at the 
10
th
 hour post procedure from baseline value
104
. 
The hs-CRP levels between STEMI and NSTEMI patients in group I at the 3 
time periods were not different (P=0.132,0.241and 0.379) in our study as opposed to 
the findings by Habib et al
114
 in serum CRP levels which was seen to be increased in 
STEMI patients.  
The similarity in salivary hs-CRP expression among our study groups should 
be further studied by comparison to serum levels. In one study
77
 the salivary CRP level 
was found to be higher in periodontitis patient by a novel lab-on-chip using an 
Electronic taste chip (ETC) approach utilizing micro beads of greater surface area for 
more antigen/antibody interaction, in our study we used a high sensitive 
immunoturbidimetric assay which is used to analyse serum hs-CRP, so the use of 
saliva in the assay could have caused low expression of the specific epitope of the CRP 
antigen. 
The salivary myoglobin expression in our study was evaluated using ELISA-
sandwich technique which utilises 2 monoclonal antibodies to quantitatively detect 
myoglobin levels  showed negative expression  i.e. levels below the  absorbance level 
of the spectrometer in ELISA reader (450 nm) in 60.7% of the samples in group I , in 
16.6% of samples in group II A and 15.3% of samples in group II B, this negative 
values could be due to undetectable levels of  myoglobin in saliva or due to 
insufficient sensitivity of the technique to identify the analyte or could be due to the 
matrix effect of the sample, which could lead to masking of the target protein marker 
by other interferences in the sample
115
. 
The expression of salivary myoglobin in our study showed no difference in the 
expression levels collected at 6-12 hours from group I when compared to group II (II 
A + II B). These findings are contrary to the findings of previous studies done in 
serum myoglobin estimation which proved that myoglobin is the first marker to rise 
after MI and it peaks in 12 hours after the onset of symptoms but can be detected as 
early as 90 minutes and can be used to rule out or rule in AMI in emergency room
108, 
109, 110
.This discrepancy could be attributed to lower level of expression of myoglobin 
in saliva than in serum.  
The expression of salivary myoglobin was significantly higher in Group II A 
and II B (non-AMI controls) when compared with saliva collected at 24-48hours (P= 
0.009) and 48-72 hours (P=0.015) from group I (AMI patients) as opposed to a study 
that have shown that there is significant rise in myoglobin levels in serum as well as in 
UWS of AMI patients
111. 
This discrepancy could be explained by the fact that there 
was a difference in time of collection and storage of the samples among group I and 
group II, while the samples from AMI patients were collected over a period of 6 
months and collected from different centres in Tamil Nadu and has to be stored in the 
facility where we collected saliva at -20 degree Celsius before transportation to -70 
degree Celsius and has undergone more than one freeze-thaw cycle (at least 2 ) when 
compared to the control samples which was collected 2 months before analysis and 
from a single centre and constantly stored at the same temperature and underwent only 
a single freeze thaw cycle before analysis. This is reflected in the study, while only 
40% of the samples from group I showed positive expression, 84% of samples from 
group II A and 85% of samples from group II B showed positive expression for 
myoglobin. 
The expression of myoglobin concentration in  group I showed a significant 
increase (P=0.018) in samples collected at 6-12 hours than samples collected at 24-48 
hours and 48-72 hours. This finding is in concurrence with the kinetics of myoglobin 
which peaks at 12 hours and falls at 36 hours 
12,107
. 
The expression of salivary myoglobin concentration among STEMI and 
NSTEMI patients in group I was significantly increased (P=0.043) in the sample 
collected at 6-12 hours, which is similar to the findings in previous studies done to 
evaluate serum myoglobin for early diagnosis of AMI
108,109,110
. Moreover the 
myoglobin expression at 6-12 hours sample was higher in NSTEMI patients which is 
important as the salivary myoglobin values in absence of ECG changes can help in 
early diagnosis of AMI and prompt treatment. 
 
 
 
 
 
 
       
      
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
 
Summary and Conclusion 
     
 
 Salivary hs-CRP expression was seen in all the samples of study population 
 Expression of salivary hs-CRP were higher in group I than Group II A and II 
B, however there was no difference when multiple comparison was done.  
 Expression of salivary hs-CRP did not show any difference among group I 
samples collected at 6-12 hours, 24-48 hours and 48-72 hours. 
 Expression of salivary hs-CRP did not show any difference between STEMI 
and NSTEMI patients in group I. 
 Salivary myoglobin concentrations were expressed in 30.9% of the group I, 
84% in group II A and 85% in group II B samples. 
 Expression of salivary myoglobin concentration was higher in group II B than 
group II A which was in turn higher than group I. 
 Expression of salivary myoglobin showed a significant  increase in Group II A 
and II B samples when compared with 24-48 hours and 48-72 hours samples of 
group I (P=0.013 and P= 0.022 respectively) 
 Expression of salivary myoglobin levels within group I showed a significant 
increase in samples collected at 6-12 hours (P=0.018) than from samples 
collected at 24-48 hours and 48-72 hours. 
  Expression of salivary myoglobin levels  in group I showed a significant 
difference between STEMI and NSTEMI patients in samples collected at 6-12 
hours(P=0.043) the expression was higher in NSTEMI patients. 
 
 
 
The present study shows that hs-CRP and myoglobin can be detected both 
qualitatively and quantitatively in saliva. While hs-CRP using Immunoturbidimetry 
showed consistent results, myoglobin results by ELISA were inconsistent, this 
inconsistency we feel was due to its sensitivity to long term storage. Based on this 
finding it is preferable to analyse the samples immediately or prevent repeated freeze- 
thaw cycle. Salivary analysis of cardiac biomarkers needs more sensitive techniques 
before they can be utilised as a diagnostic tool and further studies are to be done to 
arrive at a reference range for salivary hs-CRP and myoglobin levels.  
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RATIONALE: 
 For adults with chest pain, the ECG and measures of serum biomarkers are used to 
screen and diagnose myocardial necrosis. 
These measurements require time and delays therapy and affects prognosis. 
The objective of this study is to investigate the feasibility and utility of saliva as 
an alternative diagnostic fluid for identifying biomarkers of acute myocardial 
infarction. 
 
NULL HYPOTHESIS: 
 
Levels of hs-CRP and MYO are same in the saliva and serum of AMI patients. 
 
AIM: 
To evaluate the presence of high sensitive C-reactive protein (hs-CRP), 
Myoglobin(MYO) in the unstimulated whole saliva (UWS) of acute 
myocardial infarct patients and controls. 
 
 
OBJECTIVE: 
 
 To evaluate the presence of high sensitive C-reactive protein (hs-CRP) in the 
UWS of AMI patients using Immunoturbidimetric assay (IT). 
 To evaluate the presence of myoglobin (MYO) in the UWS of AMI patients 
using Solid phase Sandwich- Enzyme linked immunosorbant assay (ELISA).  
 To evaluate the presence of hs-CRP, and MYO in the UWS of controls. 
 
MATERIALS AND METHODS: 
Study groups 
Group I     - Unstimulated saliva from 30 acute myocardial infarct patients   
Group II    - Normal subjects (controls)    
           IIA - Unstimulated saliva from 15 controls with periodontitis 
           IIB - Unstimulated saliva from 15 apparently healthy controls without 
 periodontitis 
 
Criteria used for assessing Periodontitis: 
1. Plaque scores                    more than 30% of sites 
2. Bleeding scores                more than 30% of sites 
3. Probing depth                   greater than or equal to 3mm 
           4. Clinical attachment loss     greater than or equal to 2mm 
METHOD OF COLLECTING SALIVA: 
Unstimulated saliva from AMI patients would be collected thrice, first sample   within 
6-12 hrs of onset of signs and symptoms of AMI, second sample after 24 hrs and 
before 48 hrs of onset of sign and symptoms and third sample after 48 hrs and before 
72 hrs.. The subjects would be requested to spit the saliva into a sterile container to 
collect approximately 5 ml of saliva. 
 
Unstimulated whole saliva would be collected from controls at a specific time,   
between 9 to 12 am, the subjects should be refrained from eating, drinking for at least 
1hr before evaluation. The subjects would be requested to expectorate all saliva into 
sterile container to collect approximately 5 ml of saliva. 
 
STORAGE: 
Collected samples would be stored at -70 
o 
C for further analysis.  
 
PROCEDURE:   
 
Enzyme Linked Immunosorbant Assay for Myoglobin and Immunoturbidimetric assay 
for hs-CRP estimation. 
 
STATISTICS TO BE USED:  
 
Analysis of variance (ANOVA) 
Data analysis to be done using SPSS (Statistical Package of Social Science) version17  
 
Armamentarium: 
     1.  Oral examination devices 
Gloves, Mask, Mouth mirror, Williams probe 
2. Centrifuge Tubes   (1.5ml) 
3. Micropipettes 
4. Micropipette tips ( 20µl, 100µl, 200 µl,1000 µl)  
5. Cooling Centrifuge 
6.  -70 degrees Celsius ultra low temperature storage cabinet 
      7. Sterile containers for saliva collection 
      8.   Ice pack (for transfer)    
    9.  MYOGLOBIN ELISA kit (Biocheck inc
TM
.USA) 
 Automatic washer 
 ELISA reader 
   10. HsCRP Immunoturbidimetric kit ( BioSystems S.A
TM
, Spain) 
 CS400 automatic analyser 
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………………………………….residing at                      
…………………………………………………………………………………………
…, do hereby solemnly and state as follows. I am the deponent herein; as such I am 
aware of the facts stated here under.  
I was informed and explained about the pros and cons of the study/test in the 
…………… language known to me. 
I was also informed and explained that the results of the individual test will not be 
revealed to the public. I give my consent after knowing full consequences of the 
dissertation/thesis/study and I undertake to cooperate with the doctor for the study. 
I am also aware that I am free to withdraw the consent given at any time during the 
study in writing. 
Signature of the Patient/Attendant 
The patient was explained the procedure by me and he has understood the same and 
signed in                  
 (English/Tamil/Hindi/Telugu/…………………….) before me. 
                                    
   Signature of the Doctor        
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Annexure IV- Case History Data- Group II (IIA + II B) 
CAS
E 
NO 
SAMP
LE NO 
DATE AGE  
GEN
DER 
GINGI
VITIS 
PERIODONTI
TIS 
SYST.DISEA
SES 
HABI
TS 
HsCR
P 
(mg/L
) 
MYO   (ng/ml) 
1 CP 05 11.9.12 52 M YES Gen.Chronic Type 2 DM 
Smoki
ng 
    
2 CP 06 13.9.12 35 M YES Localised NIL NIL 0.69 4.264 
3 CP 07 15.9.12 42 M YES Localised NIL NIL 0.62 0.208 
4 CP 08 20.9.12 63 M YES Gen.Chronic Type 2 DM NIL 0.48 1.953 
5 CP 09 22.9.12 45 M YES Gen.Chronic NIL 
Smoki
ng 
0.68 10.23 
6 CP 10 25.9.12 52 M YES Gen.Chronic NIL NIL 0.24 -1.09 
7 CP 13 25.9.12 63 M YES Gen.Chronic Type 2 DM NIL 0.44 4.225 
8 CP 01 6.8.12 40 F YES 
Localised, 
severe 
NIL NIL 0.55 0.582 
9 CP 02 11.8.12 38 F YES Gen.Chronic NIL NIL 0.68 0.703 
10 CP 03 16.8.12 55 F YES Gen.Chronic HTN NIL 0.59 0.774 
11 CP 04 17.8.12 50 F YES Gen.Chronic NIL NIL 3.18 272.4 
12 CP 11 20.8.12 60 F YES Gen.Chronic Type 2 DM NIL 0.57 22.24 
13 CP 12 20.8.12 41 F YES Localised. NIL NIL 0.5 -5.58 
14 CP 14 2.9.12 59 F YES Gen.Chronic NIL NIL 0.63 2.139 
15 CP 15 6.9.12 35 F YES Localised NIL NIL 0.63 1.693 
16 CN 01 16.8.12 40 M NO NO NIL NIL 0.52 5.344 
17 CN 03 16.8.12 55 M NO NO NIL NIL 0.71 10.74 
18 CN 08 20.8.12 30 M NO NO NIL NIL     
19 CN 09 10.9.12 31 M NO NO NIL NIL     
20 CN 12 12.9.12 43 M NO NO NIL NIL 0.57 -2.022 
21 CN 13 14.9.12 65 M NO NO NIL NIL 0.79 2.098 
22 CN 02 18.8.12 54 F NO NO NIL NIL 0.55 1.034 
23 CN 04 19.8.12 55 F NO NO NIL NIL 0.87 0.682 
24 CN 05 19.8.12 45 F NO NO NIL NIL 0.55 3.542 
25 CN 06 20.8.12 35 F NO NO NIL NIL 0.59 11.63 
26 CN 07 20.8.12 40 F NO NO NIL NIL 0.62 16.85 
27 CN 14 16.9.12 40 F NO NO NIL NIL 0.72 8.259 
28 CN 16 22.8.12 40 F NO NO NIL NIL 0.69 3.894 
29 CN 17 8.11.12 34 F NO NO NIL NIL 0.62 -5.79 
30 CN 18 8.11.12 34 F NO NO NIL NIL 0.35 0.971 
           
           
           
           
CASE NO 1, 18 AND 19 SAMPLES WERE NOT INCLUDED  
BECAUSE OF SAMPLE CONTAMINATION    
CASE NO 11 AND 12 SAMPLES WERE NOT INCLUDED IN RESULTS 
BECAUSE OF ABNORMAL VALUES 
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